Molecular bases of the modulation of coagulation factor levels by Caruso, Pierpaolo
Universita` degli Studi di Ferrara
DIPARTIMENTO DI BIOCHIMICA E BIOLOGIA MOLECOLARE
Corso di Dottorato di Ricerca in Biochimia Biologia Molecolare e Biotecnologie
Ciclo XXI
Coordinatore Prof. Francesco Bernardi
Molecular bases of the modulation of coagulation factor levels
Settore Scientifico Disciplinare BIO/11
Candidato:
Pierpaolo Caruso
Tutore:
Ch.mo Prof. Francesco Bernardi
Anni 2006-2008
Contents
1 General Introduction 1
1.1 Hemostasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2 Blood coagualtion . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 Clotting factors . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.4 Clotting factors levels . . . . . . . . . . . . . . . . . . . . . . . 11
1.5 Level’s analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2 Combined effect of hemostatic gene polymorphisms and the
risk of myocardial infarction in patients with advanced coro-
nary atherosclerosis. 26
2.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.2 Intoduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.3 Materials & Methods . . . . . . . . . . . . . . . . . . . . . . . 28
2.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.6 Supporting Information . . . . . . . . . . . . . . . . . . . . . . 42
2.7 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3 Vitamin K-induced modification of coagulation phenotype in
VKORC1 homozygous deficiency. 47
3.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.3 Patients, materials and methods . . . . . . . . . . . . . . . . . 49
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.6 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4 Reduced FVII and FVIII levels and shortened thrombin-
generation times during a healthy diet in middle-aged women
with mild to moderate CVD risk. 65
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
I
4.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.6 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
5 Stimulation of P2 (P2X7) receptors in human dendritic cells
induces the release of tissue factor-bearing microparticles 82
5.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
5.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
5.3 Material and Methods . . . . . . . . . . . . . . . . . . . . . . 85
5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
5.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5.6 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
6 General discussion 103
6.1 General discussion . . . . . . . . . . . . . . . . . . . . . . . . 104
6.2 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
7 Summary 116
II
Abbreviation
vWF von Willebrand Factor
GPIb-V-IX Glicoprotein Ib-V-IX
II Prothrombin
IIa Thrombin
TF Tissue Factor
FV Factor V
FVa Activated FV
FVII Factor VII
FVIIa Activated Factor VII
FVIII Factor VIII
FVIIIa Activated Factor VIII
FIX Factor IX
FIXa Activated Factor IX
FX Factor X
FXa Activated Factor X
FXI Factor XI
FXIa Activate Factor XI
MPs Microparticles
PAR Protease-Activated Receptor
TAFI Thrombin Activatable Fibrinolysis Inhibitor
TFPI Tissue Factor Pathway Inhibitor
AT Antithrombin
PC Protein C
APC Activated Protein C
TM Thrombomodulin
PS Protein S
III
Chapter 1
General Introduction
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1.1 Hemostasis
Hemostasis is a dynamic process whereby blood is maintained fluid under
normal conditions, but is allowed to clot in case of trauma. It is a tightly
regulated mechanism involving various cellular and molecular components.
Blood coagulation is part of this important host defense mechanism.
In the resting state endothelial cells, that tile the walls of the blood vessels,
inhibit the platelet adherence and thus the activation of the blood coagu-
lation. Moreover, the synthesis of prostacyclin and heparin-like substances,
and the presence of protein complexes (thrombin-thrombomodulin), leading
to generation of anticoagulant proteins (activated protein C), prevent clot
formation in normal blood vessels [1].
After vessel injury, damaged endothelial cells expose negatively charged phos-
pholipids and release procoagulant proteins [2], platelets adhere to macro-
molecules in subendothelial tissues and aggregate to form the primary hemo-
static plug that temporary blocks blood loss.
The interaction between platelets and the damaged endothelium requires von
Willebrand Factor (vWF), a large multimeric plasma protein. vWF acts as a
bridge by binding to exposed collagen in the sub-endothelium and Glicopro-
tein Ib-V-IX (GPIb-V-IX), a specific receptor on platelet surface [1]. Platelets
activation triggers specific morphologic and biochemical alterations on their
membrane surface; phospholipid composition changes, resulting in negatively
charged phopshatidylserine exposure on the outer leaflet [3, 4]. Platelet α-
granules release fibrinogen, Factor V (FV), vWF and other proteins involved
in hemostasis; δ-granules secrete Calcium ions and ADP. Glycoprotein IIb-
IIIa (G-IIb-IIIa) expression on platelet membrane surface mediates interac-
tion with fibrinogen, vWF, fibronectin and platelet aggregation [1, 9].
Later, as wound healing occurs, fibrin clot are broken down and removed [5].
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1.2 Blood coagualtion
In a classical view coagulation is represented as a “cascade”or “waterfall”mo-
del, divided into two pathways: an “intrinsic pathway”, so named because all
the components are present in blood and an “extrinsic pathway”, in which
the subendothelial cell membrane protein tissue factor (TF) is required in ad-
dition to circulating components. The initiation of both pathways resulted
in activation of Factor X (FX) and the eventual generation of a fibrin clot
through a common pathway [6]. Although these concepts represented a sig-
nificant advance in the understanding of coagulation and served for many
years as a useful model, more recent clinical and experimental observations
[7] explain how the cascade/waterfall hypothesis does not fully and com-
pletely reflect the events of hemostasis in vivo [8].
A cell-based model of coagulation explain, in a more physiological way, how
coagulation cascade evolves in consequence of a vascular injury, underlaying
the roles of cellular elements. Several cells play different roles in the coagula-
tion process, due to their procoagulant and anticoagulant properties. Blood
platelets and TF-bearing Microparticles (MPs) play a major role in sup-
porting procoagulant reactions, supplying negatively charged phospholipid
essential for the correct assembly of molecular complexes. Vascular endothe-
lial cells play a key role in maintaining the anticoagulant properties of the
vasculature.
Formation of an impermeable platelet and fibrin plug at the site of vessel
injury is essential, but it is also required that procoagulant substances acti-
vated in this process remain localized on damaged site.
According to this model, coagulation pathway proceeds as a sequence of
events localized on the site of vessel injury.
1.2.1 Initiation phase
The process of blood coagulation starts by the exposure of TF-expressing
cells to flowing blood (Fig.1.1). TF is expressed constitutively on cells such as
smooth muscle cells and fibroblasts but not on resting endothelium; it is also
expressed in several other districts and constitutes an hemostatic envelope
normally not in contact with blood [9]. Disruption of the endothelium or
activation of endothelial cells or monocytes results in the exposure of TF
on blood flow [10]. Stronger evidence suggests that TF circulates in blood
exposed on the surface of MPs; that derive from various cell types : white
blood cells, endothelial cells, and platelets, and might play important roles
in development of pathological hemostasis (thrombosis) opposing to normal
clotting [11].
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Figure 1.1: Factor VIIa bound to TF activates both factor X and factor IX. Factor Xa
formed by factor VIIa/TF binds to factor Va on that cell and converts a small amount of
prothrombin to thrombin
Exposed TF interacts with Factor VII/activated Factor VII (FVII/FVIIa)
and the new-formed complex TF/FVIIa activates small amounts of FX and
Factor IX (FIX). Activated FX (FXa) associates with its cofactor, activated
Factor V (FVa), and forms the so called “prothrombinase-complex”on the
surface of the TF-bearing cells [12], and leads the activation of small quantity
of circulating Prothrombin (II) into Thrombin (IIa).
The adhesion process partially activates the platelets and promotes se-
cretion of partially activated FV from their α-granules [13].
Zymogen FV can also be activated by FXa [14] or by noncoagulant pro-
teases [15].
Low level activity of the TF pathway probably occurs at all times in the
extravascular space. The coagulation proteins leave the vasculature, perco-
late through the tissues, and are found in the lymph roughly in proportion to
their molecular size [16]. Thus, FVII is probably bound to extravascular TF
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even in the absence of an injury[12], and the extravascular FX and FIX can
be activated as they pass through the tissues. This idea is consistent with the
finding that low levels of the activation peptides from coagulation factors are
present in the blood of normal individuals [17]. This process does not lead
to clot formation under normal circumstances, because the really large com-
ponents of the coagulation process, platelets and Factor VIII (FVIII)/vWF
complex, are kept sequestered in the vascular space. Coagulation only pro-
ceeds when damage to the vasculature allows platelets and Factor VIII/vWF
exposure into the extravascular tissues.
1.2.2 Amplification phase
The small amount of thrombin generated on the TF-bearing cell in the ini-
tiation phase, has several important functions; one of that is activation of
platelets. Although platelets have already adhered at the site of injury and
become partially activated, the addition of thrombin can induce a higher level
of procoagulant activity than adhesive interactions alone [18]. As a result
platelets release partially activated forms of FV onto their surfaces.
Another function of thrombin formed during the initiation phase is the
activation of the cofactors FV and FVIII on the activated platelet surface.
In this process, the FVIII/vWF complex is dissociated, permitting vWF to
mediate additional platelet adhesion and aggregation at the site of injury
(Fig. 1.2).
Thrombin also activates Factor XI (FXI), activated by the prekallekrein/ki-
ninogen/Factor XII cascade in the classic “intrinsic parhway”, which acts as
a “booster”of thrombin generation on the platelet surface [19, 20]. This
finding also strengthen the hypothesis that the intrinsic mechanism gives no
contribute to in vivo coagulation process.
By the end of the amplification phase, the “stage”is set for large-scale throm-
bin generation in the propagation phase.
1.2.3 Propagation phase
The propagation phase of clot formation occurs on the surface of activated
platelets. First, activated-Factor IX (FIXa) generated during the initiation
phase can now bind to its cofactor, activated-Factor VIII (FVIIIa), on the
platelet surface, assembling in the so called “tenase-complex”.
Second, additional FIXa can be supplied by platelet-bound activated-FactorXI
(XIa).
Third, because FXa cannot move effectively from the TF-bearing cell to the
activated platelet, FXa must be provided directly on the platelet surface by
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the FIXa/FVIIIa complex.
Fourth, the FXa rapidly associates with FVa bound to the platelet during
the amplification phase, producing a burst of thrombin generation of suf-
ficient magnitude to clot fibrinogen [9, 21, 22]. Hence more than 95% of
the total amount of thrombin production takes place after initial clot forma-
Figure 1.2: On the surface of an activated platelet, factor IXa formed on the TF-bearing
cell can incorporate into a Xase complex. Addition factor IXa is formed by plateletbound
factor XIa. Factor Xa formed on the platelet surface is channeled into IIase complexes,
leading to a burst of thrombin generation. Because factor XI is activated on the platelet
surface by thrombin, PK, HK, and factor XII are not required for thrombin generation in
this model.
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tion, during propagation phase [23]. This excess of thrombin has been pro-
posed to play an important role in stabilizing the clot by: activating Factor
XIII (FXIII), the fibrin stabilizing factor [24]; cleaving the platelet protease-
activated receptor-4 (PAR-4), that contribute to full activation of human
platelets [25]; activating thrombin activatable fibrinolysis inhibitor (TAFI)
[26]. TAFI is a carboxypeptidase that removes terminal lysine residues from
fibrin, thereby removing potential binding sites for fibrinolytic enzymes and
enhancing clot resistance to fibrinolysis [27]. Greater levels of thrombin ac-
tivity are needed to activate TAFI than to form a fibrin clot. Failure in TAFI
activation is thought to contribute significantly to the bleeding tendency in
hemophilia [28].
1.2.4 Termination phase
Once a fibrin platelet clot is formed over a damaged area, the clotting process
must be limited to avoid thrombotic occlusion in other normal areas of the
vasculature [12].
The TF/FVIIa activity is inhibited by the Kunitz type inhibitor, Tissue Fac-
tor Pathway Inhibitor (TFPI) [29–31], secreted by endothelium. TFPI binds
to FXa forming a quaternary complex with TF/FVIIa that quickly limits
coagulation [35].
The serine protease inhibitor Antithrombin (AT)[32] neutralize enzymes of
the coagulation system; its physiological role is to protect the circulation
from free enzymes and limit the coagulation process to sites of vascular in-
jury. Circulating AT is a relatively inefficient serpin, but its activity is stim-
ulated by heparin and presumably by heparin-like molecules such as sulfated
glycosaminoglycans that are synthesized and expressed by endothelial cells
[34]. The increasing efficiency of AT by heparin is the molecular basis for
the use of heparin as a therapeutic anticoagulant. Antithrombin is the major
thrombin-inactivating protein [33].
TFPI and AT inhibit coagulation acting directly against proteins and macro-
molecular complexes, instead another mechanism act in an indirect way
switch off coagulation.
The protein C (PC) anticoagulant system inhibits the procoagulant func-
tions of FVIIIa and FVa, the cofactors in the tenase and prothrombinase
complexes respectively [36, 37].
The key component in the system is protein C, a vitamin K-dependent zy-
mogen (proenzyme), activated by thrombin bound to the membrane protein
thrombomodulin (TM) on the surface of intact endothelial cells. Activated
PC (APC) cleaves a few peptide bonds in each of the phospholipid membrane
bound cofactors FVa and FVIIIa. APC can also cleave the intact form of
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FV, converting FV to an anticoagulant cofactor of APC in the inactivation
of FVIIIa in the tenase complex [9].
APC activity is enhanced by another vitamin Kdependent inhibitory cofac-
tor, protein S (PS). In human plasma, about 30% of protein S circulates as
free protein; the remaining is bound to the complement regulatory protein
C4b-binding protein. Only the free form of PS functions as a cofactor to
APC.
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1.3 Clotting factors
Procoagulant and anticoagulant proteins are composed of multiple structural
domains. Among the different proteins, these domains have both a high de-
gree of structural and functional homology.
1.3.1 Signal peptide
Both procoagulant and anticoagulant proteins found in plasma are initially
synthesised with a signal peptide. This usually highly hydrophobic short
peptide, needed for translocation of the growing polypeptide chain into the
endoplasmatic reticulum, is cleaved off prior to secretion.
1.3.2 Propeptide/γ-Carboxyglutamic Acid-Rich Domain
All vitamin K-dependent proteins, prothrombin, FVII, FIX, FX, PC PS,
contain a γ-Carboxylation recognition site located on the propeptide domain
between the signal peptide and the γ-Carboxyglutamic Acid-Rich domain
(Gla domain). This region directs, in a Vitamin-K dependent mechanism,
γ-Carboxylation of the γ-Carboxyglutamic acid residues located in the adja-
cent, approximately 40 AA residues long Gla domain. Gla domain is crucial
for the Ca2+ mediated binding of these proteins with negatively charged
membranes. After carboxylation the propeptide is cleaved off.
1.3.3 Epidermal Growth Factor Domain
Several procoagulant and anticoagulant proteins contain two or more epi-
dermal growth factor (EGF)-like domains. These domains are about 43 to
50 amino acid residues in length and their structure is determined by three
typical disulfide-bonds. The function of EGF-like domains on many clotting
proteins, although not fully understood, appears to be involved in the for-
mation of protein complexes. The EGF-like domains in FVII are important
for the binding to TF. The second EGF-like domain of Factor IX contains a
binding site for activated FVIII. The second EGF-like domain of protein C
has been shown to be involved in the binding of protein S. The TM’s binding
sites for thrombin and PC are located on the fifth and the fourth EGF-like
domains, respectively.
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1.3.4 Kringle Domain
Kringle domains are about 100 amino acid residues in length and charac-
terised by a pattern of three disulfide bonds. These domains are likely to
be involved in protein complex formation. Only two procoagulant proteins,
prothrombin and FXII contain kringle domains. The second kringle of pro-
thrombin probably contains the main binding site for activated factor V.
1.3.5 Catalytic Domain: Serine Protease Module
The catalytic domain of all procoagulant enzymes have an active site and
an internal core that is nearly identical to that of trypsin. Conversion of an
inactive proenzyme to an active enzyme depends on limited proteolysis and
for some proteins the cleavage of so-called activation peptides.
The enzyme activity of all clotting proteases depends on a serine, an aspartic
acid and a histidine within the active site, which is characteristic for all serine
proteases. The molecular surfaces surrounding the active site are responsible
to specifically define the enzyme substrate [38].
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1.4 Clotting factors levels
Within the vast majority of the healthy population the range of pro and
anticoagulant components varies significantly. Counting the only thrombin
generation, the responsiveness for a given TF initiating dose in the healthy
population is quite extraordinary different [39].
The basis for the heterogeneity of the procoagulant response in human pop-
ulation is probably a consequence of both genetic and environmental factors,
which influence the status of the proteomic phenotype when evaluated in
either a healthy or pathological state [40].
Recently has been estimate that there are 24500 human protein coding genes
[45]; considering all molecular mechanisms that fold a protein from a primary
mRNA transcript to the final physiologic function, e.g. alternative splicing
and post translational modification, we might estimate a huger amount of pri-
mary transcript protein products. The initial peptide product and most of its
biosynthetic modifications are dictated primarily by genetics, with each mod-
ification system under the direction of multiple genes. A variety of instruc-
tions are included in the genetic package for the primary product which tar-
get the protein through multiple, chemically driven assembly and transport
processes which also incorporate additional post-translational modifications.
The completed, modified, intracellular product must be further processed
proteolytically at multiple sites prior to export. In addition, extracellular
modifications, by both biologically directed processes and environmental ac-
cidents, may further alter the circulating product. As a consequence of all
these modification events, the number of members of the phenotypic pro-
teome will probably extend well over the million(s) range [40].
In addition other elements could influence the variation of circulating clotting
proteins; it has been reported that even with equivalent genetic deficiencies,
there is a wide range of expression of risk events, either thrombotic or hemor-
rhagic, suggesting that multiple genetic, acquired and environmental factors
influence the possibility of an individual to undergo a clinically significant
hemorrhagic or thrombotic event.
Concomitant presence of genetic defects in an individual, so called “gene-
gene interaction”, also influence the normal or predicted levels of clotting
factor.
It is well established that plasma concentrations of several clotting factors,
i.e. fibrinogen, FVII, FVIII, vWF, FIX, FXII, high molecular-weight kinino-
gen, and prekallikrein, increase with progressing age in healthy humans [46].
Moreover, in elderly people there are seasonal variation in fibrinogen concen-
tration and the highest plasma levels have been observed during the coldest
months [47, 48]. However, high plasma levels of the coagulation activation
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markers in older populations do not necessarily reflect a high risk of arterial
or venous thrombosis [49].
Disease states, drug consumption, and also human behavior or attitude i.e.
smoking, diet, sedentariness, could in such aspect influence clotting factor
levels, conditioning the fragile hemostatic balance.
Hence, only a few information dealing with the meaning of the heterogeneity
of the plasma vitamin K-dependent proteins or the influence of this hetero-
geneity on their biological performance with respect to activation, catalytic
function or turnover is available.
1.4.1 “Normal”proteins levels
Various coagulation proteins circulate in blood at very different concentra-
tions related to their specific roles in the blood coagulation system [56–59].
Table 1.1 Coagulation Factor Levels
Factor Plasma concentration µg/mL
Fibrinogen 3000
Prothrombin 9
Factor V 10
Factor VII 0.5
Factor VIII 0.1
Factor IX 5
Factor X 8
Factor XI 5
Factor XII 30
Factor XIII 10
Protein C 4
Protein S (free) 10
Prekallikrein 50
High molecular weight kininogen 70
AntithrombinIII 290
Fibrinogen is the predominant clotting factor having a concentration that
is approximately 30 000-fold higher than that of FVIII. The high level of fib-
rinogen is required for the formation of the fibrin clot, whereas the low con-
centration of FVIII is more than sufficient to support FIXa in the activation
of FX. Taking into account other vitamin K-dependent proteins, FVII is the
least abundant, FIX and FX have intermediate levels and prothrombin cir-
culating at the highest concentration. Several studies conducted in knockout
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mice may help in understanding relative importance of various coagulation
factors in vivo [60].
The embryonic lethal phenotype, associated with TF deficiency, demon-
strates the crucial importance of the TF pathway [61–63], also confirmed
by the absence of natural TF deficiency in humans.
FVII deficient mice develop normally in utero but die shortly after birth
due to severe bleeding [64]. The difference in severity between TF and FVII
knockout animals suggests a role for TF during embryogenesis in fibrin for-
mation.
Prothrombin and FV deficiency are associated with partial embryonic lethal-
ity and fatal haemorrhage [65–67]. In contrast, FIX and FVIII-deficient mice
develop normally in utero but acquire haemophilia-like disease after birth
[68, 69].
Fibrinogen-deficient mice have normal fetal development and suffer a moderate-
to-severe bleeding phenotype similar to human fibrinogen deficiency [70].
This shows that thrombin generation is more important than fibrin deposi-
tion.
Mice deficient in TAFI have no pathologic phenotype, demonstrating that
TAFI deficiency is fully compatible with life [71].
Hemostasis is based on anticoagulant protein too. No TFPI deficiency are
described in humans, which may indicate that lack of TFPI is not compat-
ible with life; TFPI knockout mice have a lethal phenotype suffering from
uncontrolled activation of coagulation with consumption of coagulation fac-
tors [72].
Homozygous AT knockout mice have a lethal phenotype, demonstrating the
importance of the protein for control of coagulation [73].
The protein C system is physiologically very important, which is clearly
demonstrated by the severe thromboembolic disease associated with homozy-
gous deficiency of protein C in both man and mice [74]. Mice lacking the
protein C or TM genes are affected by a lethal phenotype, actually TM
deficiency is particularly severe affecting embryogenesis even before the de-
velopment of a functional cardiovascular system [75, 76].
Within healthy population, there is a wide range of hemostatic pheno-
type; as a result it is difficult to define the “edge”of normal/abnormal, or
pathologic, clotting factors levels.
Since thrombin plays a central role in formation of the primary hemostatic
plug, the total amount of thrombin formed and the rate of its generation
could provide a good reflection of the potential coagulation activity; but an
effective clot cannot be formed without adequate levels of procoagulant fac-
tors.
The levels of coagulation factors in plasma of normal individuals vary amply
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(generally 50% to 150% of the level in normal pooled plasma), as evaluated
in several papers [39–44]. This suggests that a wide range of factor levels
is compatible with normal hemostatic function. However, even within the
normal range, variations can affect the thrombin generation [41].
The effect of coagulation factors levels on thrombin generation’s pattern
is complex. For most of the coagulation factors, changing the level between
50% and 150% has little effect on the rate and pattern of thrombin genera-
tion [41, 50].
Decreasing level of factors VIII, IX, or XI to < of 50% results in a mod-
est decline in thrombin generation, with a dramatic decline only after levels
fall below 10% to 20% of normal. Thus, the wide range of levels found in
the normal population probably has little effect on thrombin generation and,
therefore, little effect on hemostatic function. The pattern for FX is little
different than the other factors. Again, changes between 50% and 150% have
essentially no effect on thrombin generation. However, thrombin generation
is maintained down to FX levels as low as 1% to 5% in in vitro experiments
before falling off sharply [50, 51]. Thus, variation in FX levels probably con-
tributes little to the pattern of thrombin generation unless combined with a
deficiency of other factors.
The relationship between prothrombin levels and thrombin generation is dif-
ferent from the other coagulation factors, actually total amount of thrombin
produced are proportional to the prothrombin level [41]. The rate of throm-
bin generation activity achieved during clot formation significantly affect the
structure and stability of the resulting fibrin clot [52]. This means that any
variation in prothrombin level is reflected in the pattern of thrombin genera-
tion and could have an effect on the hemostatic effectiveness of the resulting
clot.
The relationship between prothrombin level and thrombin generation is achiev-
able also for supernormal prothrombin concentrations: elevated plasma pro-
thrombin results in an increase in the rate and amount of thrombin gen-
eration. This may be the reason that elevated levels of prothrombin are
correlated with a risk of arterial and venous thrombosis [53].
FVIII and FXI levels above the normal range result in a modest increase
in the rate of thrombin generation, and elevated levels of these factors have
been reported to be associated with the risk of thrombosis [54, 55].
1.4.2 Inherited and acquired coagulation disorder
As already mentioned, the hemostatic Vitamin K-dependent factors of coagu-
lation are encoded by genes with virtually identical exon/intron distributions
[77], suggesting that they have evolved relatively recently from a common an-
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cestor by a process of gene duplication and divergence [78]; in this context it
is believable that both the genes and the proteins have common regulatory
mechanisms.
It has been provided the direct quantification of the genetic and environ-
mental correlations between the plasma levels of a group of closely related
vitamin K-dependent hemostasis factors, i.e. prothrombin, factor VII, IX,
X, PC and functional PS. This investigation indicates how, actually, a set of
common genes affects for a large proportion the phenotypic variation in vita-
min K-dependent proteins, and similarly how a set of common unmeasured
environmental factors also appears to influence plasma levels of vitamin K-
dependent proteins [79].
A major contributor to our understanding of the complex hemostatic process,
however, has occurred because of individuals with hereditary deficiencies of
molecular elements fundamental to the hemostatic pathway.
Bleeding disorders
Genetic defects causing bleeding disorders can affect different proteins in the
coagulation process.
The most common forms of haemophilia are due to different types of ge-
netic defects (deletions, insertions, point mutation) resulting in inherited
deficiency of FVIII (haemophilia A) or FIX (haemophilia B). Other coagula-
tion factor deficiencies are very rare [82, 83]. Haemophilias occur in severe,
moderate and mild forms, corresponding plasma levels being <1% of the
normal plasma concentration, 1-5% and 5-30% respectively [83]. In the most
common human hemophilias, the linkages between the degree of pathology
and the molecular severity of the mutations are also not always correlated
[86]. These observations imply that the genetic/environmental background
in which a gene deficiency is observed may produce very different phenotypic
responses.
von Willebrands disease (vWD) is a relatively common bleeding disorder af-
fecting both males and females [85]. vWF is important for platelet adhesion
and for maintaining the normal level of FVIII [87, 88], thus patients with
vWD could have a primary haemostasis defect, caused by deficient adhesion
of platelets to exposed subendothelial collagen, or, associated to severe forms
of vWD, a secondary deficiency of FVIII, as the vWF is a carrier of FVIII
in blood.
Faulty platelet function or thrombocytopenia can cause bleeding defects but
clinically important bleeding only occurs when the abnormalities are severe
[80, 81]. The symptoms associated with the inherited platelet disorders rarely
are severe haemorrhage. Inherited deficiency of GPIb-V-IX (Bernard-Soulier
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syndrome) is characterized by thrombocytopenia, giant platelets and lack
of vWF binding and affected individuals have bleeding tendency. Acquired
platelet function defects can originate by different medication (e.g. aspirin)
and by different chronic diseases such as renal failure or autoimmune disease.
Combined deficiency of the vitamin K-dependent coagulation proteins is an-
other very rare inherited cause of bleeding. This may be caused by ge-
netic defects in one of the two known enzymes that are involved in the
γ-carboxylation of the vitamin K-dependent coagulation proteins: the γ-
carboxylase and the vitamin K epoxide reductase [89].
Acquired bleeding problems can also be related to deficiency of vitamin
K, which is required in the biosynthesis of many of the coagulation pro-
teins. Malabsorption of the lipidsoluble vitamin K results in deficient γ-
carboxylation of the vitamin K-dependent coagulation proteins, which in
severe cases may result in increased bleeding. Even more common is vitamin
K deficiency due to excessive intake of vitamin K antagonists, e.g. warfarin,
used as anticoagulant therapy.
Bleeding disease can be due to the development of autoantibodies against a
coagulation factor, the most common is directed against FVIII [90–93]. These
conditions mainly affect elderly people. The molecular mechanisms respon-
sible for the development of the autoantibodies are poorly understood.
In disseminated intravascular coagulation (DIC), acquired bleeding is due
to the consumption of platelets and coagulation factors due to widespread
pathological proteolysis [93, 95]. In this condition, multiple proteolytic en-
zyme systems including the coagulation and fibrinolytic systems are activated
causing microvascular thrombosis and major disturbances of the capillary
circulation. DIC may complicate malignancy, traumatic injury, surgery or
pregnancies, and is often caused by severe infections with septicaemia.
Thrombotic disorders
Epidemiological studies illustrate that significant thrombotic risk is asso-
ciated with the inheritance of common mutations (polymorphisms) which
influence functions or concentrations of coagulation proteins and cells [96].
But determining the global risk for thrombotic events (venous and arterial)
is difficult because thrombosis is a multicausal disorder. The pathogenesis of
thrombosis involves inherited and acquired risk factors. Most acquired risk
factors are of short duration, like pregnancy, surgery, and immobilization;
other are environmental factors, such as obesity [97, 98], oral contraception
[99, 100], hormone replacement therapy [100], age [101], alcohol use [102]
and potentially smoking [103]; in addition there are lifelong inherited fac-
tors. Thus, a thrombotic episode may appear to be induced by an acquired
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risk factor when in fact the disease is due to a combination of genetic and
acquired risk factors. The natural balance between pro- and anticoagulant
forces is affected by most of the inherited risk factors for thrombosis.
The majority of the genetic risk factors impair the function of the protein C
anticoagulant system. The most common, found in 20-40% of patients with
thrombosis, is a single point mutation in the FV gene, which keeps full pro-
coagulant capacity but causes the APC resistance phenotype (FV Leiden).
This mutation impairs degradation of mutant FVa by APC, causing the loss
of one APC cleavage sites in FVa. Furthermore impairs the degradation of
FVIIIa, because mutant FV shows poor anticoagulant-cofactor activity for
APC in the degradation of FVIIIa.
A single point mutation (G20210A) in the 3’ untranslated region of the pro-
thrombin gene is the second most common genetic risk factor for thrombosis
(three- to five-fold increased risk) found in 68% of patients with thrombosis
and in around 2% of healthy controls [104–106]. The prothrombin func-
tion is unaffected by the mutation but the levels of prothrombin in plasma
are slightly increased as a result of the mutation, which may be the basis
for the increased risk. Also other impairment in providing normal levels of
FVIII [107], FIX [108], FXI [109] and fibrinogen [110] have been reported
to be independent risk factors of venous thromboembolism (VTE). Mech-
anisms through which these modifications could influence thrombotic risk,
however, are not completely understood. Most individuals with a single ge-
netic risk factor, although they have a lifelong increased risk, will not suffer
from thrombosis during their lives because the associated risk is relatively
low. People affected by more than one risk factor, either genetic or acquired
are at higher risk and it is now considered that venous thromboembolism is
a typical multigenetic/multifactorial disease.
The antiphospholipid syndrome (lupus anticoagulant) is an acquired risk fac-
tor for both arterial and venous thrombosis [111–113]. Pregnant women with
the antiphospholipid syndrome have an increased risk of spontaneous abor-
tions.
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1.5 Level’s analysis
It is a well known problem in clinical hematology that traditional coagulation
tests, such as the prothrombin time (PT) and activated partial thromboplas-
tin time (APTT), do not assess the whole coagulation system. These tests
use clot formation as their endpoint, which occurs when only around 5% of
all physiologically relevant thrombin is formed [114, 115] and also are insensi-
tive to prothrombotic states. Coagulation factor assays can identify specific
deficiencies but these do not always closely correlate with the clinical pheno-
type. Hence neither the prothrombin time, nor the activated partial throm-
boplastin time, nor the level of the individual clotting factors can accurately
predict the presence and severity of a bleeding tendency. The observation
that thrombin generation varies up to 40-fold when measurements are done
with individual coagulation factors at the extremes of the normal ranges in
a synthetic plasma system [39], also demonstrate the limitations of the tra-
ditional tests.
Thrombin is the central enzyme in the coagulation cascade; estimation of an
individuals potential to generate thrombin may correlate more closely with
a hyper- or hypo-coagulable phenotype, compared to traditional coagulation
tests. Measurement of an individuals capacity to generate thrombin, how-
ever, captures the end result of the interaction between proteases and their
inhibitors and is therefore potentially more useful as a reflection of a throm-
botic (high thrombin generation) or haemorrhagic (low thrombin generation)
phenotype compared to conventional coagulation tests [116].
Controlled TF concentration used to trigger the assay may evidence differ-
ent role of procoagulant proteins among coagulation cascade. The positive
feedback activation of thrombin by the intrinsic pathway can only be demon-
strated at low (<1 pmol/L) TF concentrations [117]. Furthermore the assay
is sensitive to FVIII and FIX at TF concentrations up to 5 pmol/L [118].
Small differences in TF concentration can therefore cause significant dif-
ferences in the thrombin generating potential of plasma. Low TF trigger
concentration may exacerbate differences in thrombograms, the thrombin
generation curve, of patients with the same pathology, e.g. hæmophilia; in-
stead higher quantity could masks this result due to the decreased sensitivity
of the system [119]. Conversely, thrombin generation measurements at low
TF concentrations in hæmophilia are difficult because of the low signal ob-
tained and it may not always be possible to obtain full curves [119], limiting
the information gained from the measurements. Low TF concentrations are
also needed to demonstrate the protein C independent effect of protein S on
anticoagulant process [120].
Also FIXa could be used as trigger in order to measure the effect of FVIII
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on thrombin generation. FIXa was found to be sensitive to differences in
thrombin generation at very low FVIII concentrations [121]. Even if throm-
bin generation assay in common laboratory usage is not sensitive to the
actions of the protein C pathway, in vitro sensitivity can be increased by
adding truncated human recombinant thrombomodulin (sTM) [122], APC
[123], or the snake venom Protac [124, 125]. The use of these agents makes
the assay more sensitive to deficiencies in protein C (not detected if APC
is used), protein S, FV R506Q (factor V Leiden) and conditions associated
with acquired protein C resistance.
Thus thrombin generation measurements can be performed in several
ways that have different sensitivities for various haemostatic or thrombotic
defects. As small variations in pre-analytical variables can cause significant
changes in the sensitivity for these defects, results cannot be interpreted
without detailed information on how the assay was performed. Since throm-
bin is the central enzyme in the coagulation cascade, evaluating hypothetical
thrombin generation based upon the individuals blood composition may cor-
relate more closely with a hyper- or hypo-coagulable phenotype, compared to
traditional coagulation tests. Finally, even when a single well standardized
test is available it is unlikely that it will be suitable in all situations and
separate modified tests designed for specific clinical situations may need to
be developed.
19
Bibliography
[1] Furie B, et al. Cell, 1988, 53: 505-518
[2] Pearson JD. Baillieres Best Practice & Research: Clinical Haematology, 1999,
12: 329-341.
[3] Bevers EM, et al. European Journal of Biochemistry, 1982, 122: 429-436.
[4] Bevers EM, et al. Biochimica et Biophysica Acta, 1983, 736: 57-66.
[5] Riddel J P, et al. Journal of Pediatric Oncology Nursing, 2007, 24(3): 123-131.
[6] Luchtman-Jones L, et al. Annals of Medicine, 1995, 27(1): 47-52.
[7] Kleinschnitz C, et al. Journal of Experimental Medicine, 2006, 203(3): 513-518.
[8] Hoffman M, et al. Thrombosis and Haemostasis, 2001, 85: 958-965.
[9] Dahlback B. Journal of Internal Medicine, 2005, 257: 209-223.
[10] O’Shaughnessy D, et al. Pratical hemostasis and thrombosis. Malden, MA:
Blackwell Publishing ltd, 2005.
[11] Osterud B, et al. Seminars in Thrombosis and Hemostasis, 2006, 32: 11-23.
[12] Hoffman M. Journal of Thrombosis and Thrombolysis, 2004, 16(1/2): 17-20.
[13] Briede JJ, et al. Thrombosis and Haemostasis, 2001, 85: 509-513.
[14] Monkovic D, et al. Biochemistry, 1990, 29: 1118-1128.
[15] Allen DH, et al. Journal of Biological Chemistry, 1995, 270: 1408-1415.
[16] Miller GJ, et al. Thrombosis and Haemostasis, 2000, 83: 427-432.
[17] Bauer KA, et al. Blood, 1990, 76: 731-736.
[18] Alberio L, et al. European Journal of Clinical Investigation, 1999, 29: 1066-
1076.
20
[19] Baglia FA, et al. Biochemistry, 1998, 37: 2271-2281.
[20] Oliver JA, et al. Blood, 2002, 100: 539-546.
[21] Hoffman M. Journal of Thrombosis and Thrombolysis, 2004, 16(1/2): 17-20.
[22] Loscalzo J. S. A. I. Thrombosis and hemorrhage (3rd ed.), 2003, Philadelphia:
Lippincott Williams & Wilkins.
[23] Mann KG, et al. Thrombosis and Haemostasis, 2003, 1: 1504-1514.
[24] Lorand L. Annals of the New York Academy of Sciences, 2001, 936: 291-311.
[25] Ofosu FA. Transfusion and Apheresis Science, 2003, 28(3): 265-8.
[26] Bajzar L, et al. Journal of Biological Chemistry, 1995, 270: 14477-84.
[27] Nasheim M. Current Opinion in Hemathology, 1998, 5: 309-313.
[28] Mosnier LO, et al. Thrombosis and Haemostasis, 2001, 86: 1035-39.
[29] Rapaport S.I. Blood, 1989, 73: 359.
[30] Broze GJ, et al. Biochemistry, 1990, 29: 7539.
[31] Broze GJ Jr. Journal of Thrombosis and Haemostasis, 1995, 74: 90.
[32] Van ’t Veer C, et al. Journal of Biological Chemistry, 1997, 272(7): 4367-77.
[33] Beresford CH, et al. International Journal of Biochemistry, 1990, 22(2), 121-8.
[34] Weitz JI. Journal of Clinical Investigation, 2003, 111: 952-4.
[35] Kumar V, et al. Robbins and Cotran: Pathologic basis of disease (7th ed.),
2005, Philadelphia: Elsevier.
[36] Dahlback B, et al. The molecular basis of blood disease, 2001, 3 ed., Philadel-
phia: WB Saunders Company: 614-56.
[37] Esmon CT. Chest, 2003, 124(s3): 26-32.
[38] Stassen JM, et al. Current medicinal Chemistry, 2004, 11: 2245-2260.
[39] Butenas S, et al. Blood, 1999, 94(7), 2169-2178.
[40] Mann GK, et al. Journal of Thrombosis and Haemostasis, 2004, 2: 1727-34.
[41] Allen GA, et al. Journal of Thrombosis and Haemostasis, 2004, 2: 402-413.
[42] Dielis AWJH, et al. Journal of Thrombosis and Hæmostasis, 2008, 6: 125-31.
21
[43] Hockin MF, et al. Journal of Biological Chemistry, 2002, 277: 18322-33.
[44] Brummel-Ziedins KE, et al. Journal of Thrombosis and Hæmostasis, 2004, 2:
281-8.
[45] Venter JC, et al. Science, 200, 291(5507): 1304-51.
[46] Kannel WB, et al. Journal of the American Medical Association, 1987, 258:
1183-86.
[47] Frohlic M,et al. Atherosclerosis Thrombosis and Vascular Biology, 1997, 17:
2692-97
[48] Stout RW, et al. Age Ageing, 1996, 17: 3321-25.
[49] Mari D, et al. Experimental Gerontology, 2008, 43: 66-73.
[50] Al Dieri R, et al. Thrombosis and Haemostasis, 2002, 88: 576-582.
[51] Allen GA, et al. Blood Coagulation and Fibrinolysis, 2000, 11(s1): S3-S7.
[52] Wolberg AS, et al. Blood, 2003, 101: 3008-3013.
[53] Poort S, et al. Blood, 1996, 88: 3698-3703.
[54] Meijers JC, et al. New England Journal of Medicine, 2000, 342: 696-701.
[55] Maede TW, et al. Lancet, 1980, 1: 1050-1054.
[56] Mann KG, et al. Methods in Enzymology, 1993, 222: 1-10.
[57] Furie B, et al. New England Journal of Medicine, 1992, 326: 800-6.
[58] Davie EW. Thrombosis and Haemostasis, 1995, 74: 1-6
[59] Stenflo J. et al. The molecular basis of blood disease, 2001, 3 ed., Philadelphia:
WB Saunders Company, 579-613.
[60] Carmeliet P, et al. Cardiovascular Research, 1998, 39: 8-33.
[61] Carmeliet P, et al. Nature, 1996, 383, 73-5.
[62] Toomey JR, et al. Blood, 1996, 88, 1583-7.
[63] Bugge TH, et al. Proceedings of the National Academy of Sciences of the
USA, 1996, 93: 6258-63.
[64] Rosen ED, et al. Nature, 1997, 390: 290-4.
22
[65] Sun WY, et al. Proceedings of the National Academy of Sciences of the USA,
1998, 95: 7597-602.
[66] Xue J, et al. Proceedings of the National Academy of Sciences of the USA,
1998, 95: 7603-7.
[67] Cui J, et al. Nature, 1996, 384: 66-8.
[68] Bi L, et al. Nature Genetics, 1995, 10: 119-21.
[69] Kundu RK, et al. Blood, 1998, 92: 168-74.
[70] Suth TT, et al. Genes and development, 1995, 9: 2020-33.
[71] Nagashima M, et al. Journal of Clinical Investigation, 2002, 109: 101-10.
[72] Huang ZF, et al. Blood, 1997, 90: 944-51.
[73] Ishiguro K, et al. Journal of Clinical Investigation, 2000, 106: 873-8.
[74] Jalbert LR, et al. Journal of Clinical Investigation, 1998, 102: 1481,8.
[75] Rosenberg RD. Thrombosis and Haemostasis, 1997, 78:705-9.
[76] Weiler H, et al. Journal of Thrombosis and Haemostasis, 2003, 1: 1515-24.
[77] Tuddenham EGD, et al. Oxford University Press, 1994.
[78] Patthy L. Seminars in Thrombosis and Haemostasis, 1990, 16: 245-59.
[79] Souto JC, et al. Thrombosis and Haemostasis, 2001, 85: 88-92.
[80] George JN. Lancet, 2000, 355: 1531-9.
[81] Majerus PW. The molecular basis of blood disease, 2001, 3 ed., Philadelphia:
WB Saunders Company: 764-90.
[82] Mannucci PM, et al. Blood, 2004, 104: 1243-52.
[83] Mannucci PM, et al. New England Journal of Medicine, 2001, 344: 1773-9.
[84] Bolton-Maggs PH, et al. Lancet, 2003, 361(9371): 1801-9.
[85] Mannucci PM. New England Journal of Medicine, 2004, 351: 683-94.
[86] Aledort L. Pthophysiology of Haemostasis and Thrombosis, 2003, 33: 2-3.
[87] Sadler JE. Annual Review in Biochemistry, 1998, 67: 395-424.
[88] Ruggeri ZM. Journal of Thrombosis and Haemostasis, 2003, 1: 1335-42.
23
[89] Zhang B, et al. Journal of Thrombosis and Haemostasis, 2004, 2: 1564-72.
[90] Collins PW. Blood Coagulation and Fibrinolysis, 2003, 14(s1): s23-7.
[91] Kraemer DM, et al. Journal of Internal Medicine, 2003, 254: 301-3.
[92] Delgado J, et al. British journal of Haematology, 2003, 121: 21-35.
[93] Hay CR. Baillieres Clinical Haematology, 1998, 11: 287-303.
[94] Levi M. British Journal of Haematology, 2004, 124: 567-76.
[95] Dempfle CE. Thrombosis and Haemostasis, 2004, 91: 213-24.
[96] Rosendaal FR. Haemostasis, 1999, 29(s1): 1-9.
[97] Romano M, et al. Journal of Clinical Endocrinology & Metabolism, 2003,
88(11): 5321-5326.
[98] Rauramaa R, at al. Medicine & Science in Sports & Exercise, 1999, 31(S11):
S631-4.
[99] Rosendaal FR, et al. Journal of Thrombosis and Hæmostasis, 2003, 1(7):
1371-80.
[100] Rosing J, et al. American Journal of Obstetric & Gynecology, 1999, 180(6
Pt 2): S375-82.
[101] Haapanen-Niemi N, et al. Preventive Medicine, 1999, 28(4): 343-348.
[102] Catena C, et al. Journal of Hypertension, 2003, 21(2): 281-8.
[103] Thorneycroft IH, et al. Journal of Reproductive Medicine 2003, 48(S11):
911-920.
[104] Rosendaal FR. Lancet, 1999, 353: 1167-73.
[105] Nicolaes GA, et al. Hematology/oncology clinics of North America, 2003,
17: 37-61.
[106] Bertina RM. Clinical Chemistry, 1997, 43: 1678-83.
[107] Koster T, et al. Lancet, 1995, 345: 152-5.
[108] Van Hylckama Vlieg A, et al. Blood, 2000, 95: 3678-82.
[109] Maijers JCM, et al. New England Journal of Medicine, 2000, 342: 696-701.
[110] Koster T, et al. Thrombosis and Hæmostasis, 1994, 71: 719-22.
24
[111] Levine JS, et al. New England Journal of Medicine, 2002, 346: 752-63.
[112] Arnout J. Thrombosis and Haemostasis, 2001, 86: 83-91.
[113] Triplett DA. Haemostasis, 1996, 4: 358-67.
[114] Hemker et al. Thrombosis and Hæmostasis, 1995, 74: 134-8.
[115] Rand MD, et al. Blood, 1996, 88: 3432-45.
[116] van Veen JJ, et al. British Journal of Hæmatology, 2008, 142: 889-903.
[117] Keularts IM, et al. Thrombosis and Hæmostasis, 2001, 85: 1060-5.
[118] van Veen JJ, et al. Blood Coagulation and Fibrinolysis, 2008, 19: 183-9.
[119] Lewis SJ, et al. British Journal of Hæmatology, 138: 775-82.
[120] Sere KM, et al. Blood, 104: 3624-30.
[121] McIntosh JH, et al. Journal of Thrombosis and Hæmostasis, 2003, 1: 1005-
11.
[122] Van Hylckama Vlieg A, et al. British Journal of Hæmatology, 2007, 138:
769-74.
[123] Regnault V, et al. Pathophysiology of Hæmostasis and Thrombosis, 2003,
33: 23-9.
[124] Gatt A, et al. Thrombosis and Hæmostasis, 2003, 98: 691-2.
[125] Hezard N, et al. Thrombosis and Hæmostasis, 2007, 97: 165-6.
25
Chapter 2
Combined effect of hemostatic gene
polymorphisms and the risk of myocardial
infarction in patients with advanced coronary
atherosclerosis.
Martinelli N, Trabetti E, Pinotti M, Olivieri O, Sandri M, Friso S, Pizzolo
F, Bozzini C, Caruso P, Cavallari U, Cheng S, Pignatti PF, Bernardi F, Cor-
rocher R, Girelli D.
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2.1 Abstract
Relative little attention has been devoted until now to the combined effects
of gene polymorphisms of the hemostatic pathway as risk factors for Myocar-
dial Infarction (MI), the main thrombotic complication of Coronary Artery
Disease (CAD). The aim of this study was to evaluate the combined ef-
fect of ten common prothrombotic polymorphisms as a determinant of MI.
Methodology/Principal Findings We studied a total of 804 subjects, 489
of whom with angiographically proven severe CAD, with or without MI (n=
307; n= 182; respectively). An additive model considering ten common poly-
morphisms [Prothrombin 20210G>A, PAI-1 4G/5G, Fibrinogen β-455G>A,
FV Leiden and R2, FVII -402G>A and -323 del/ ins, Platelet ADP Receptor
P2Y12 -744T>C, Platelet Glycoproteins Ia (873G>A), and IIIa (1565T>C)]
was tested. The prevalence of MI increased linearly with an increasing num-
ber of unfavorable alleles (χ2 for trend = 10.68; P= 0.001). In a multiple
logistic regression model, the number of unfavorable alleles remained signif-
icantly associated with MI after adjustment for classical risk factors. As
compared to subjects with 3-7 alleles, those with few (≤2) alleles had a de-
creased MI risk (OR 0.34, 95%CIs 0.13-0.93), while those with more (≥8)
alleles had an increased MI risk (OR 2.49, 95%CIs 1.03-6.01). The number
of procoagulant alleles correlated directly (r = 0.49, P= 0.006) with endoge-
nous thrombin potential. Conclusions The combination of prothrombotic
polymorphisms may help to predict MI in patients with advanced CAD.
2.2 Intoduction
Myocardial Infarction (MI), the leading complication of coronary atheroscle-
rotic disease (CAD), generally occurs in the late stages of disease because
of coronary thrombosis superimposed on a ruptured/unstable plaque [1]. In
clinical practice it is well-known that, in spite of the documented presence
of advanced CAD, only a subset of patients develops acute MI during their
life-course [2]. The reasons for individual differences in susceptibility to MI
are poorly understood. In principle, subjects with an increased tendency
to form blood clots (i.e. with hypercoagulability) may be at increased risk,
as observed for venous thrombosis. Lessons from animal models suggest
that excessive thrombin generation may be particularly harmful during the
later stages of atherosclerosis, when thrombotic complications often occur
[3,4]. However, this is difficult to assess in clinical practice, since we lack a
unique and reliable laboratory marker of hypercoagulability [5]. Moreover,
functional tests evaluating concentration and/or function of blood coagu-
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lation proteins are often subjected to multiple transient interferences, e.g.
due to the use of antithrombotic and anticoagulant agents or the presence
of concomitant inflammation. Genetic polymorphisms with a documented
functional effect on blood coagulation proteins may represent a useful tool,
by reflecting the individuals lifelong exposure to even a mild prothrombotic
state. During the last decade, extensive studies on various individual poly-
morphisms as risk factors for CAD and MI have yielded largely inconclusive
results [6-11]. These results reflect at least two critical issues: 1) the multifac-
torial and multistep pathogenesis of CAD, involving many different biochem-
ical pathways and intermediate phenotypes (e.g. hyperlipidemia, diabetes,
hypertension), each in turn under the control of many different genes; 2) the
enormous heterogeneity of investigations in terms of study design, typology of
patients included, and clinical endpoints [10]. There has also been relatively
little attention devoted to assess the combined effect of genes, which might be
anticipated by analogy to the well-known additive effects of conventional risk
factors. Generally, individual polymorphisms confer a marginal to moderate
CAD risk that becomes evident only across many thousands of individuals,
as was recently demonstrated by meta-analysis for Factor V 1691 G>A (Fac-
tor V Leiden), prothrombin 20210 G>A, and PAI-1 -675 4G/5G [8]. This
renders such polymorphisms unhelpful in assessing individuals risk clinically.
On the other hand, the value of analyzing multiple alleles simultaneously for
determining the risk is not well studied.
In this study we evaluated the combined effect of ten common genetic
variants, with known modest effects on the hemostatic balance (listed in
Table 2.1) [6,12-21], in modulating the risk of development of MI. Because
of the relatively late occurrence of MI in the natural history of CAD, we
focused on a selected population of high risk patients with angiographically
documented, advanced CAD. A thrombin generation assay was also used in
a subset of patients to explore the propensity to form blood clot as a function
of the number of hemostatic polymorphisms.
2.3 Materials & Methods
2.3.1 Study population
This study was performed within the framework of the Verona Heart Project,
a regional survey aimed to search for new risk factors for CAD and MI in
subjects with objective angiographic documentation of their coronary ves-
sels. Details about enrolment criteria have been described in detail elsewhere
[35,36]. A total of 804 subjects, for whom complete analyses of 10 polymor-
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Table 2.1: Description of the haemostatic gene polymorphisms, analysed in this study,
and their associated intermediate phenotype.
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phisms of genes involved in hemostatic pathways were available, were in-
cluded in the present study. Three-hundred fifteen subjects had completely
normal coronary arteries, being submitted to coronary angiography for rea-
sons other than CAD, mainly valvular heart disease (CAD-free group). These
controls were also required to have neither history nor clinical or instrumen-
tal evidence of atherosclerosis in vascular districts beyond the coronary bed.
Fourhundred eighty nine subjects had angiographically proven CAD (the ma-
jority of them being candidates for coronary artery bypass grafting) with ob-
jective documentation of presence/absence of MI. The disease severity was
determined by counting the number of major epicardial coronary arteries
(left anterior descending, circumflex, and right) affected with ≥1 significant
stenosis (≥50%). According to the hypothesis to be tested, subjects with
non-advanced CAD (i.e. coronary stenosis <50%) were not included in the
study. Cardiologists unaware that the patients were to be included in the
study assessed the angiograms. Patients were classified into MI (n= 307)
and non-MI (n= 182) subgroups on the basis of a thorough review of medi-
cal records including history, electrocardiogram, enzyme changes, and/or the
typical sequelae of MI on ventricular angiography.
All participants came from the same geographical area (Northern Italy),
with a similar socio-economic background. At enrolment, a complete clinical
history was collected, including the assessment of cardiovascular risk factors
such as obesity, smoking, hypertension and diabetes. The study was approved
by the Ethic Committee of our Institution (Azienda Ospedaliera, Verona).
A written informed consent was obtained from all the participants after a
full explanation of the study.
2.3.2 Biochemical analysis
Samples of venous blood were drawn from each subject at enrolment, before
coronary angiography and after an overnight fast. Serum lipids, as well as
other CAD risk factors, including high-sensitivity C-reactive protein (hs-
CRP) were determined as previously described [26].
2.3.3 Genetic analysis and nomenclature
Genomic DNA was extracted from whole blood samples by a phenol-chloroform
procedure using the Puregene kit (Gentra Systems) according to the manu-
facturers protocol. The 10 genetic polymorphisms, selected on the basis of
prior evidence of potential functionality in modulating the hemostatic path-
way, are listed in Table 2.1. Seven out of ten polymorphisms (fibrinogen
beta-chain - 455G>A, Factor VII A1/A2, Factor V Leiden, Prothrombin
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20210 G>A, PAI-1 -675 5G/4G, GP IIIa Leu33Pro, GP Ia/IIa alfa2 873
G>A) were examined by a previously described and validated linear-array
assays for candidate markers [37]. The accuracy of the linear-array genotyp-
ing system as compared with standard genotyping approaches reported else-
where [35,36] was evaluated and the findings provide reassurance regarding
the validity of the system used, as previously described [38]. The remaining
three (Factor VII - 402 G>A, Factor V R2, P2RY12 H1/H2) were analyzed
by previously described, standard genotyping approaches [36,39,40]. Geno-
type interpretation for each polymorphism was performed independently by
two investigators and very few samples (<1%) with unclear result were re-
genotyped.
2.3.4 Measurement of thrombin generation activity
This assay was performed in a subset of CAD patients on samples drawn
at enrolment, in order to evaluate a possible functional counterpart of an
increasing number of prothrombotic alleles in terms of propensity to form
blood clot. Plasma sample were centrifuged at 23,000 g at 4◦C for 1 hour
before testing. Calibrated automated thrombin activity measurement was
conducted according to Hemker et al. [41,42] in a microtiter plate fluo-
rometer (Fluoroskan Ascent, ThermoLabsystems, Helsinki, Finland) using
the Thrombinoscope software (Synapse BV, Maastricht, The Netherlands).
The assay was carried out at 37◦C essentially as previously reported [43].
Coagulation was triggered in platelet poor plasma by recalcification in the
presence of 1 pM recombinant human tissue factor and 4 µM phospholipids.
Thrombin generation was then evaluated overtime by exploiting a specific
fluorogenic substrate (Z-Gly-Gly-Arg-AMC). Thrombin generation measure-
ment was conducted in parallel in plasma samples after the addition of a
thrombin calibrator provided by the manufacturer (Synapse BV). The soft-
ware enables the estimate of the following parameters: a) the Lag Time
of thrombin generation, b) the time to reach the maximum concentration of
thrombin (time to Peak), c) the maximum concentration of thrombin (Peak),
d) the total duration of thrombin generation activity (Start Tail), and e) the
total amount of thrombin activity assessed as the area under the curve, i.e.
the endogenous thrombin potential (ETP). All experiments were carried out
in duplicate.
2.3.5 Statistics
Calculations were performed mainly with SPSS 13.0 statistical package (SPSS
Inc., Chicago, IL). Distributions of continuous variables in groups were ex-
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pressed as means±standard deviation. Logarithmic transformation was per-
formed on skewed variables, for whom geometric mean with 95% confidence
interval (CI) are given. Quantitative data were assessed using the Students
t-test or by ANOVA with Tukeys post-hoc comparison of the means. Correla-
tions between quantitative variables were assessed using Pearsons correlation
test. Qualitative data were analyzed with the χ2-test or the Fisher exact-test
when indicated. Hardy-Weinberg equilibrium was tested for each genotype
within each group by means of χ2-test. A value of P<0.05 was considered
statistically significant.
Within each group examined, the frequencies of the genotypes associated
with each of the polymorphisms were compared by the χ2- test, with the
values predicted on the basis of the Hardy-Weinberg equilibrium. To assess
the extent to which gene polymorphisms were associated with MI, odds ra-
tios with 95% CIs were estimated by univariate logistic regression analysis.
Adjustment for other variables (i.e. number of affected vessels, age, sex,
smoking, BMI, LDL- and HDL-cholesterol) was performed by adding those
covariates in a set of multiple logistic-regression models.
The existence of gene-gene interactions was first explored by a data min-
ing technique similar to the Adaboost algorithm, and based on classifica-
tion and regression trees (CART): the gradient boosting machine [44]. The
statistical significance of the interactions found with this method was then
estimated by the likelihood ratio test applied on two logistic models (with
and without the interaction terms). After observing that no significant in-
teraction was present, we focused on an additive model. On this basis, we
attributed to each patient a prothrombotic score (PS), reflecting the sum
of 10 concomitant unfavourable prothrombotic alleles, theoretically ranging
from 0 (no prothrombotic allele present) to 20 (all the prothrombotic alleles
present). The association between the prothrombotic score and MI was eval-
uated by χ2 for linear trend analysis. The prothrombotic score was analysed
by logistic regression both as continuous variable and as categorised variable.
Odds ratios with 95% CIs were estimated by univariate logistic regression
analysis and then by multiple logistic regression with adjustment for num-
ber of affected vessels, age, sex, smoking, BMI, LDL- and HDLcholesterol.
The predictivity of our models was then evaluated by the receiver-operating-
characteristics (ROC) curve, estimating the area under the curve (AUC).
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2.4 Results
2.4.1 Haemostatic polymorphisms in the CAD group
as a whole versus CAD-free subjects
Supplemental Table 1 (Table S1) shows the genotype frequencies for each of
the 10 polymorphisms in CAD-free (n=315; males 66.0%; mean age 59.26±11.9
years) and in CAD subjects (n=489; males 83.6%; mean age 60.36±9.3
years). All alleles were in Hardy- Weinberg equilibrium. For each polymor-
phism there was no significant difference in genotype distribution between
CAD and CAD-free groups. The distribution of the prothrombotic score
(PS) in the whole study population (n=804) is shown in figure 2.1A. The
score ranged from 0 (1 subject) to 10 prothrombotic alleles (7 subjects),
with a median level of 5. Figure 2.1B shows the distribution of the PS in
CAD-free and in CAD subjects. No association was found between the PS
and CAD (P=0.889 by χ2-test).
2.4.2 Individual haemostatic polymorphisms and MI
risk in subjects with advanced CAD
Supplemental Table 2 (Table S2) shows the general characteristics of the
CAD population divided in two groups on the basis of presence/absence
of MI. As compared to CAD patients without MI, MI patients were sig-
nificantly younger, more frequently males, had a higher degree of CAD in
terms of number of diseased vessels, and lower HDL-cholesterol levels. No
significant difference was found for the other variables. Table 2.2 shows the
genotype frequencies of the 10 genetic variants in CAD patients with or with-
out MI. Two polymorphisms, factor VII -402 G>A and fibrinogen β-chain
-455 G>A, showed nominal association with MI at the univariate analysis.
However, these associations were no longer significant after multiple logistic
regression adjusted for sex, age, disease severity, smoking status, BMI, LDL-
and HDLcholesterol (P =0.155 for factor VII -402 G/A and P= 0.998 for
fibrinogen β-chain -455 G/A).
2.4.3 Combined effect of haemostatic polymorphisms
and MI risk
No significant interaction was found by CART among polymorphisms in de-
termining MI risk (all P for interaction >0.05). As shown in figure 2.1C, the
proportion of CAD patients with MI increased progressively with increasing
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number of unfavourable alleles (χ2 for linear trend= 10.68; P= 0.001). In
a multiple logistic regression model the prothrombotic score remained sig-
nificantly associated with MI after adjustment for sex, age, degree of CAD,
smoke, BMI, LDL- and HDL-cholesterol (OR for 1-point increase in pro-
thrombotic score= 1.22 with 95%CI 1.06-1.39, P =0.004). Using the median
of PS as cut-off, CAD patients with >5 alleles had a significantly increased
risk of MI as compared to subjects with ≤5 alleles (OR 2.02 with 95%CI
1.27-3.21, P= 0.003, by multiple logistic regression). Using approximately
the 5th and the 95th percentiles of PS distribution (i.e. 2 and 8, respectively),
the study population could be classified into in 3 subgroups: a low-risk group
with less than 3 unfavourable alleles (n= 26), an intermediate-risk group with
3 to 7 unfavourable alleles (n= 417), and a high-risk group with more than
7 unfavourable alleles (n= 46). The prevalence of MI among these groups
increased progressively (38.5% in low-risk; 62.6% in intermediate- risk; and
78.3% in high-risk; P= 0.001 by χ2 for linear trend), while they were similar
for the other clinical and laboratory variables (data not shown). Considering
the intermediate-risk group as the reference group, carriers of <3 alleles had
a lower risk of MI, while carriers of >7 alleles had an increased risk (Fig-
ure 2.2). Comparing the two extreme groups, the subjects with >7 alleles
had a remarkably higher MI risk (OR 7.28 with 95%CI 2.01-26.36, P= 0.002
adjusted by multiple logistic regression). The ROC curve for information
provided by our polygenic approach for MI prediction in CAD patients is
plotted in Supplemental Figure 1 (Figure S1). The AUC was 0.581 with a
95% CI from 0.530 to 0.632.
2.4.4 Combined effect of haemostatic polymorphisms
and thrombin generation activity
To get insights on the pathophysiological effect of combined hemostatic al-
leles, we assessed the characteristics of thrombin generation activity curves
as a function of the number of procoagulant alleles (i.e. fibrinogen β-chain
-455 A, Prothrombin 20210 A, Factor V Leiden, Factor V R2, Factor VII
A1, Factor VII -402 A and PAI-1 -675 4G). Since this assay pertains only to
the coagulation pathway, the three platelet-related polymorphisms were not
considered for this analysis. This assay was performed in a subset of 29 CAD
patients (26 males and 3 females, 22 with and 7 without MI), selected among
those without possible confounders (i.e. concomitant anticoagulant therapy
or overt signs of inflammation, documented by hs-CRP,5 mg/l), in order to
form three groups matched for age and sex representing the previously de-
fined risk groups (low-risk: n= 9, 8 males and 1 female, mean age 53.7±8.5;
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Figure 2.1: Study population (n = 804) stratified on the basis of number of risk alleles
(1A). The distribution of number of risk alleles in CAD-free (n = 315) and in CAD patients
(n = 489) (1B) and in CAD patients with (n = 307) or without a history of MI (n = 182)
(1C).
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intermediate-risk: n =10, 9 males and 1 female, mean age 57.8±7.4; high-
risk: n =10, 9 males and 1 female, mean age 56.0±8.6). The number of
procoagulant alleles was significantly associated with ETP and with Start
Tail, but not with Lag Time, Peak or Time to Peak (Table 2.3). Similarly,
subjects with a high number of procoagulant alleles (≥5) had significantly
higher ETP values as compared to subjects with fewer alleles (Table 2.4).
These two groups were similar not only for age and sex, but also for smok-
ing, hypertension and diabetes (data not shown). Their median thrombin
generation activity curves are showed in Figure 2.3.
2.5 Discussion
Evidence that a hypercoagulable state is associated with increased mortality
has been provided by some recent studies [11,22]. To our knowledge, this is
the first study that attempts to look at the impact of the combined effect of
several common prothrombotic polymorphisms in the identification of CAD
patients at different risk of developing MI. To put our results into perspective,
we propose the following considerations.
2.5.1 Single haemostatic polymorphisms and MI risk
This study focused on relatively few genetic variants associated with de-
fined biochemical alterations. While some of them (i.e. Factor V Leiden
and prothrombin 20210 G>A) are established risk factors for venous throm-
boembolism, their association with arterial thrombosis is much less convinc-
ing [6,9]. Here too, despite some nominal significant P values, we found no
consistent association when each polymorphism was considered individually.
Indeed, CAD and MI are paradigms of complex disease, in which the effect of
individual genes on the risk is anticipated to be weak [23,24]. Moreover, em-
phasizing the principle that “the highest the allele effect, the lowest the allele
frequency”[25], it is plausible that genetic variants such those investigated in
the present study, relatively frequent in the general population, could have
at best only a mild effect on a potentially lethal phenotype like MI. Indeed,
until now only a recent large meta-analysis including tens of thousands of
patients has been able to detect a moderate but significant increase in the
risk of coronary disease associated with either the Factor V Leiden mutation
or the prothrombin 20210A variant [8].
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Table 2.2: Genotypes frequencies (%) of the CAD population, with or without MI.
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Figure 2.2: OR for MI in groups stratified on the basis of number of unfavourable alleles.
The intermediate group (from 3 to 7 unfavourable prothrombotic alleles), representing the
85.3% of the whole population, is considered as reference group.
Table 2.3: Correlations between number of procoagulant alleles and different character-
istics of thrombin generation activity. The analysis was performed in a subgroup of CAD
patients (n = 29) without anticoagulant therapies and without signs of overt inflammation.
Procoagulant alleles were fibrinogen beta-chain -455 A, Prothrombin 20210 A, Factor V
Leiden, Factor V R2, Factor VII A1, Factor VII -402 A, PAI-1 -675 4G.
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Table 2.4: Characteristics of thrombin activity generation curves in groups stratified on
the basis of number of procoagulant alleles, with a threshold level at 5 alleles. The analysis
was performed in a subgroup of CAD patients (n = 29) without anticoagulant therapies
and without signs of overt inflammation. Procoagulant alleles were fibrinogen beta-chain
-455 A, Prothrombin 20210 A, Factor V Leiden, Factor V R2, Factor VII A1, Factor VII
-402 A, PAI-1 -675 4G. †: by t-test.
Figure 2.3: Comparison between the median thrombin generation activity curves in
groups stratified on the basis of number of procoagulant alleles, with a threshold level at
5 alleles.
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2.5.2 Combined effect of haemostatic polymorphisms
and MI risk
Recently, a polygenic approach has been demonstrated to be a valid tool to
identify subjects at risk for another complex trait such as type 2 diabetes
[26]. A similar strategy was used in the present study, suggesting that in
subjects with advanced CAD, an increasing number of prothrombotic alle-
les may confer a significant risk of developing MI. It is biologically plausible
that the simultaneous presence of several genetic variations with modest but
defined effects on the hemostatic process could influence the risk of the ma-
jor thrombotic complication in a given CAD patient. Under certain stimuli,
such as plaque erosion or rupture, this condition may predispose to sustained
thrombin generation leading to the acute thrombotic event [2]. Accordingly,
our in vitro functional studies showed an association between the number of
procoagulant alleles and thrombin generation. The latter is known to be a
highly variable and complex phenomenon modulated by the interplay of sev-
eral factors, none of them with predominant influence, many of them under
genetic control [27]. It is noteworthy that our clinical model focused on a
homogeneous group of patients with angiographically proven advanced CAD.
Elegant studies in animal models, i.e. Factor V Leiden mice crossbred with
apolipoprotein E-deficient mice, indicates that unregulated thrombin gener-
ation is particularly harmful during the later stages of atherosclerosis. [3,4].
Conversely, a mild hypercoagulable state may be less meaningful in absence
of underlying vulnerable atherosclerotic plaques. Our results may thus apply
only to the specific clinical model of this study, and not to all CAD patients.
While it is reasonable that genetically-induced excessive thrombin genera-
tion may be clinically relevant in subjects with extensive coronary plaques,
this excess might be less influential in the atherogenetic process, where other
genetic factors (i.e. those involved in modulation of lipid metabolism, an-
tioxidant balance, and so on) may be prominent. This could explain why we
found no association between the hemostatic polymorphisms and the CAD
phenotype.
2.5.3 Study limitations and strengths
One strength of our study is the clear definition of phenotypes, allowing
comparison of patients with angiographically proven, advanced CAD, with
or without MI. The CAD population had a substantial burden of traditional
risk factors and thus represented a typical patient population seen in clinical
practice.
Our study has several limitations, including the relatively low number
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of subjects and polymorphisms and a retrospective casecontrol design. In
this setting the possible confounding of the survivor effect should also be
taken into account. The prothrombotic score, calculated as the sum of pro-
thrombotic alleles, is likely an oversimplification, since it standardized the
contribution of each gene variant and does not allow distinguishing the pos-
sible different transmission models, as well as the different biological weight
of the polymorphisms. Nevertheless, for complex traits the presence of ad-
ditive effects of many genes is considered more likely than interactive ef-
fects [28,29], and additive models have been shown to perform well, even
when the underlying model is unknown [30,31]. This study can be viewed as
hypothesis-generating, shedding light into the potential usefulness of a poly-
genic approach in appropriate clinical contexts. Indeed, the predictive power
of our additive genetic model was relatively low, yielding an area under the
ROC curve (AUC) of 0.58. The AUC is a measure of the discriminatory
power of a test, ranging from 0.5 for no discriminatory power to 1 for a per-
fect test [32]. We tested only ten polymorphisms here, and there is reason to
believe that the predictive power of genetic information could be greater. In-
creasing technological resources with decreasing costs are likely to allow the
inclusion, in models similar to that used in the present study, of other genetic
variants reproducibly associated to functional consequences on coagulation
factors, either newly identified (i.e. the long-anticipated genetic modulators
of Factor VIII), or not included in this study (i.e. Factor XIII Val34Leu).
With larger data sets, it may also be possible to capture gene-gene and gene-
environmental factors.
2.5.4 Conclusions
Our data support the idea that, while individual genetic susceptibility vari-
ants are of limited clinical use, the combined information from a number
of these variants can permit the identification of groups of people at high
and low risk of developing a complex trait such asMI [33,34]. The polygenic
model used in this study, considering the cumulative effect of hemostatic
gene variants, was significantly associated to some in vitro measurements
of thrombin generation. In the specific context of advanced CAD, similar
approaches may be useful as surrogate markers of the propensity to form
blood clots leading to MI. Further studies on larger samples are needed to
confirm this intriguing working-hypothesis, as well as to improve predictive
modelling.
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2.6 Supporting Information
Table S1 Genotypes frequencies (%) in CAD-free and in CAD subjects.
Found at: doi:10.1371/journal.pone.0001523.s001 (0.08 MB DOC)
Table S2 Characteristics of the CAD population, with or without MI.
Found at: doi:10.1371/journal.pone.0001523.s002 (0.06 MB DOC)
Figure S1 ROC for the information provided by our polygenic model of
prothrombotic alleles after fitting a logistic regression model.
Found at: doi:10.1371/journal.pone.0001523.s003 (0.05 MB DOC)
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Chapter 3
Vitamin K-induced modification of
coagulation phenotype in VKORC1
homozygous deficiency.
Marchetti G, Caruso P, Lunghi B, Pinotti M, Lapecorella M, Napolitano M,
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3.1 Abstract
Background: Combined vitamin K-dependent clotting factor (VKCF) defi-
ciency type 2 (VKCFD2) is a rare bleeding disorder caused by mutated vita-
min K 2,3- epoxide reductase complex subunit 1 (VKORC1) gene. Methods
and results: An Italian patient with moderate to severe bleeding tendency
was genotyped, and found to be homozygous for the unique VKORC1 muta-
tion (Arg98Trp) so far detected in VKCFD2. The activity levels of VKCFs
were differentially reduced, and inversely related to the previously estimated
affinity of procoagulant factor propeptides for the γ-carboxylase. The normal
(factor IX) or reduced antigen levels (other VKCFs) produced a gradient in
specific activities. Vitamin K supplementations resulted in reproducible, fast
and sustained normalization of PT and APTT. At 24 h the activity/antigen
ratios of VKCFs were close to normal, and activity levels were completely
(factor VII and IX), virtually (prothrombin, factor X and protein C) or par-
tially (protein S) restored. Thrombin generation assays showed a markedly
shortened lag time. The time to peak observed at low tissue factor concen-
tration, potentially mimicking the physiological trigger and able to highlight
the effect of reduced protein S levels, was shorter than that in pooled nor-
mal plasma. At 72 h the thrombin generation times were normal, and the
decrease in activity of procoagulant VKCFs was inversely related to their
half-life in plasma. The improved coagulation phenotype permitted the un-
eventful clinical course after invasive diagnostic procedures. Conclusions:
Modification of coagulation phenotypes in VKCFD2 after vitamin K supple-
mentation was clinically beneficial, and provided valuable patterns of factor
specific biosynthesis, half-life and decay.
3.2 Introduction
Impaired γ-carboxylation [1,2] produces multiple deficiency of vitamin K-
dependent coagulation factors (VKCFD), a rare bleeding disorder inherited
as an autosomal recessive trait [3]. The VKCFD type 2 (VKCFD2) is caused
by defective regeneration of vitamin K hydroquinone by the vitamin K 2,3-
epoxide reductase complex subunit 1 (VKORC1) [4]. Only one causative
missense change (VKORC1 Arg98Trp) has been found in the homozygous
condition in families of Lebanese and German origin [5,6].
In VKCFD2, the activity of the γ-glutamyl carboxylase enzyme, impaired
by the limiting concentration of the vitamin K hydroquinone, can be tran-
siently restored by vitamin K supplementation. These features make this con-
dition an ideal model to investigate in vivo the temporal variations in levels
48
of vitamin K-dependent factors, driven by changes in γ-glutamyl carboxyla-
tion activity. Comparison of this natural condition with the pharmacological
inhibition of the vitamin K cycle could provide valuable information to in-
terpret observations obtained in plasma of patients on anticoagulant therapy
[7-11].
The study of plasma phenotype variation in VKCFD2 would also con-
tribute to validate, through in vivo observations, the cellular and molecular
investigations [4,12-16] aimed at dissecting the mechanisms through which
components of the vitamin K cycle [17] participate in the regulation of circu-
lating factor level activity. Moreover, an extended analysis of levels after vi-
tamin K supplementation in VKCFD2 would also provide information about
the natural decay of vitamin K dependent clotting factors, of great interest
for replacement therapy in inherited coagulation disorders [18].
As a thorough characterization of this deficiency by single factor parame-
ters and by assays integrating the contribution of procoagulant and anticoag-
ulant components has not been reported, we have investigated an VKCFD2
Italian patient over time after vitamin K supplementation.
3.3 Patients, materials and methods
3.3.1 Patient and family
The proposita, a 34-year-old woman, had experienced since childhood re-
peated nose and gum bleeds, menorrhagia, a severe post-partum hemorrhage
at the age of 23 requiring blood transfusions, hemoperitoneum following ovar-
ian cyst rupture, and rectal bleeding. In addition she presented with osteo-
porosis.
Laboratory testing of the patient’s plasma revealed reduced activity levels
of several procoagulant factors. Family members showed coagulation param-
eters in the normal range. Informed consent was obtained from the family
members entering this study.
3.3.2 DNA analysis
The screening of the molecular defect responsible for the altered coagulation
profile in the proposita was performed in both the γ-glutamyl-carboxylase
(GGCX) and VKORC1 genes.
Direct scanning of exons and intron-exon boundaries of GGCX and VKORC1
genes were performed by PCR amplification followed by automated sequenc-
ing with the ABI Prism 377DNASequencer (PEApplied Biosystems, Foster
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City, CA, USA). Specific primers for GGCX and VKORCI genes were derived
from the Gene Bank database (references U65896 and AY587020, respec-
tively). In the GGCX gene three single nucleotide changes, the g.1156G>C
(intron 1), the g.9167T>C (exon 9), that predicts the Arg406Arg synony-
mous change, and the g.11665G>C (intron 14) were detected.
3.3.3 Coagulation laboratory assay
Plasma samples were withdrawn before (0 h) and after (at 4, 24, 28 and 72
h) intravenous administration of 10 mg vitamin K (KonakionRoche, Basel,
Switzerland). Plasma samples before and after 24 hwere also collected during
a second course of vitamin K application conducted 5 months later, before
an esophagogastroduodenoscopy and colonoscopy with biopsy. Venous blood
was drawn in sodium citrate (12.9 mmol L−1) and immediately centrifuged
at 2000 g for 20 min at 4◦C. Plasma was separated, snap-frozen, and stored
in aliquots at -80◦C.
Factor clotting activities were assessed by conventional PT (factor (F)
II, FVII, FX and PS) or APTT -based assays (FIX and PC) with the cor-
responding commercial factor-depleted plasma (HemosILTM ; Instrumenta-
tion Laboratory, Milan, Italy). PT was also assayed in a FII, FVII, FIX
and FXdepleted bovine plasma triggered with bovine thromboplastin (Pro-
IL-Complex kit, HemosILTM). PC amidolytic activity was measured chro-
mogenically (HemosILTM Protein C).
The total activity of the protein C pathway was evaluated by the APTT-
based method Pro-Cr Global (Dade Behring Diagnostics, Marburg, Ger-
many). The normalized ratio (PCAT-NR) of the APTT determined in the
presence and in the absence of activator Protac (PCAT:PCAT/0 ratio) was
reported.
3.3.4 Antigen assays
Antigen levels were measured by ELISA using a mouse monoclonal anti-
human FVII antibody, a sheep polyclonal anti human-FVIII antibody, a
goat polyclonal anti-human FIX antibody (Affinity Biologicals Inc, Ancaster,
Canada), a rabbit polyclonal anti-human FX antibody (DakoCytomation,
Glostrup, Denmark) and a mousemonoclonal anti-human free PS antibody
(Instrumentation Laboratory) directed to the C4bBP domain. Prothrom-
bin levels were evaluated byWestern blot analysis as previously reported
for FX [19]. Upon electrophoresis of diluted patient’s plasma (1:70) on a
Novex Tris-Glycine 4-20% PAA Gel (Invitrogen, Carlsbad, CA, USA), and
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electroblotting onto nitrocellulose membranes (Schleicher & Schuell Micro-
science, Keene, NH, USA), prothrombin was probed by a sheep polyclonal
anti-human prothrombin-HRP (Affinity, Carlsbad, CA, USA). Densitomet-
ric analysis of bands was conducted by the GS-700 instrument (BIORAD,
Hercules, CA, USA).
3.3.5 FXa generation
Plasma FVII activity towards FX was assayed essentially as previously de-
scribed [20]. Generation of activated FX (FXa) was monitored continu-
ously by exploiting a specific fluorogenic substrate (MeSO2-D-CHA-Gly-
Arg-AMCAcOH, American Diagnostica, Greenwich, CT, USA). Fluorescence
(360 nm excitation, 465 emission) was measured on Spectra- FluorPlus mi-
croplate reader (TECAN, Salzburg, Austria).
3.3.6 Thrombin generation
Platelet-poor plasma (PPP) samples were centrifuged at 23 000 g at 4◦C for 1
h before testing. Calibrated automated thrombin activity measurement was
conducted according to Hemker et al. [21] in an automated microtiter plate
fluorometer (Fluoroskan Ascent; Thermo Labsystems, Helsinki, Finland) us-
ing the Thrombinoscope software (Synapse BV, Maastricht, The Nether-
lands). The assays were carried out at 37◦C essentially as previously reported
[22]. Coagulation was triggered in recalcified PPP under the following exper-
imental conditions: 4 µM phospholipids (PLP, 20% phosphatidyl serine-80%
phosphatidyl choline); 1 pM recombinant human tissue factor (TF)/4 µM
PLP; 5 pM TF/4 µM PLP; 10 pM TF/ 8 µM PLP. The snake venom Pro-
tac (HemosILTM ; Instrumentation Laboratory) was used in the presence of
3.5 pM TF/10 µM PLP. Thrombin generation was evaluated overtime by
exploiting a specific fluorogenic substrate (Z-Gly- Gly-Arg-AMC) and was
conducted in parallel in each plasma sample supplemented with a throm-
bin calibrator (Synapse BV). Experiments were carried out in duplicate or
triplicate.
3.4 Results
3.4.1 DNA studies
Sequencing of the VKORC1 gene showed that the proposita was homozygous
for the c.292C>T transition resulting in the amino acid change Arg98Trp.
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The proposita’s mother, two brothers and one sister were found to be carriers,
as indicated by the AciI restriction analysis.
Frequent polymorphisms predicting variation in coagulation factor levels
were also investigated. The proposita was found to be homozygous for the
-323 ins10 in F7 gene [23], a condition associated with a remarkable reduction
in FVII levels [24].
Table 3.1: Coagulation times and activity levels of vitamin K-dependent coagulation
factors measured before (0 h) and after vitamin K treatment. *Values obtained before and
after the second course of vitamin K administration. The APTT and PT† are expressed
in seconds (normal range 2535 s and 1827 s, respectively). The PT† was measured in
a FII, FVII, FIX and FX-depleted bovine plasma triggered with bovine thromboplastin.
PCAT-NR, normalized ratio of the APTT determined in the presence and in the absence
of the protein C activator Protac. Clotting activity (FVII, FIX, FX, FII) and amydolitic
activity (PC) levels are reported as percentage of PNP (70120, normal range). Free protein
S antigen is reported as percentage of PNP (53109, normal range). ‡FXa levels (% of PNP)
measured at the peak of the FXa generation curves.
3.4.2 Coagulation studies
To get a comprehensive evaluation of the hemostatic profile and of its varia-
tions following vitamin K supplementation, APTT and PT were measured in
the patient’s plasma before and after intravenous supplementation of 10 mg
vitamin K (Table 3.1). Before treatment the APTT was mildly prolonged
and the PT-INR was remarkably increased. At 4 h a normal APTT and a
remarkable decrease of the PT-INR were observed. The APTT was shorter
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Figure 3.1: Baseline activity level of procoagulant factors and inhibition constants (Ki)
of coagulation factor propeptides for c-carboxylase [25]. The mean activity levels measured
in two independent plasma samples are reported. Logarithmic relation between variables
(R2 = 0.70).
Figure 3.2: Decrease in activity levels (expressed as percentage) from peak to 72 h and
half-life of procoagulant factors. The lowest values in the half-life range [26] were used (R2
= 0.97, exponential curve).
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than that of PNP (30 s) both at 24 and 28 h, and at the same time points PT
was normalized. At 72 h the beneficial effects of vitamin K supplementation
were noticeable, particularly for APTT.
Variations in PT and APTT were evaluated in the light of level variations
of the specific vitamin K-dependent factors.
Procoagulant factors
The baseline activity levels, measured on different occasions (Table 3.1),
were constant for FX and showed modest (FVII and FIX) or pronounced
(prothrombin) variations.
As the differentially reduced activity values might reflect the residual car-
boxylase activity, we investigated their relationship with the binding affinities
of carboxylase for the propeptide of the vitamin K-dependent procoagulant
factors, previously estimated through peptide inhibition constants [25]. In
two plasma samples obtained 5 months apart before vitamin K supplementa-
tion, mean activity levels showed a logarithmic relation (R2 = 0.70) with the
inhibition constants (Fig. 3.1). The best relation was found for FVII, FX
and prothrombin levels (R2 = 0.99), which indicated that their activity was
Figure 3.3: Activity/antigen ratios measured before (white column) and after vitaminK-
treatment (black column). For PC the anticoagulant/amydolitic activity ratio is reported.
The antigen levels are indicated. Prothrombin antigen levels were evaluated by densito-
metric analysis of Western blot.
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inversely related with the affinity of the vitamin K-dependent carboxylase
for coagulation factor propeptides.
For all factors an appreciable and reproducible (Table 3.1) increase in ac-
tivity levels was measured after vitamin K supplementation. Plasma activity
levels reached normal values for FVII and FIX, and borderline values for FX
and prothrombin.
Levels higher than those at baseline were still detectable at 72 h, with the
exception of FVII, which decreased at pretreatment levels (Table 3.1). The
decrease in levels from the peak to 72 h was inversely related to (Fig. 3.2) the
known half-life values of coagulation factors [26]. Particularly, the decrease
showed the best fitting (exponential curve, R2 = 0.97) with the lowest values
of the half-life range. The R2 using the highest half-life values was 0.75.
Defective VKOR activity appeared to affect activity and secretion of vi-
tamin K-dependent factors to a different extent, and was responsible for the
presence of dysfunctional molecules in plasma, as indicated by an excess of
antigen levels (Fig. 3.3). FIX antigen levels were normal at baseline whereas
those of FVII and FX were similarly reduced. At 24 h antigen levels were
restored (FVII) or remarkably increased (FX).
The activity/antigen ratios at baseline and their variations induced by
vitamin K supplementation after 24 h are summarized in Fig. 3.3. Before
vitamin K administration, the unbalance between activity and antigen levels
was remarkable with ratios of 0.2 (FX), 0.3 (FIX) and 0.5 (FVII and FII),
which would strongly indicate the presence of partially carboxylated forms
of vitamin K dependent clotting factors (PIVKA).
The overall dysfunctional effect of poorly carboxylated forms was indi-
cated by PT assays conducted in a FII, FVII, FIX and FX-depleted bovine
plasma triggered with bovine thromboplastin (Table 3.1). The PT observed
in the patient (107 s, 5% of PNP) was more prolonged than those measured
in plasma from patients on anticoagulant therapy (range 44-89 s, 7-28% of
PNP).
Vitamin K administration substantially increased activity/antigen ratios
of all procoagulant factors. The increase in amount of functional molecules
was also indicated by the amelioration of parameters of PT and APTT assays
(Table 3.1). However, the PT obtained in the bovine plasma (clotting time
37 s and 42% activity) was still far from normal (18-27 s).
As expected, the antigen level of FVIII (1.31 IU mL−1), not requiring
vitamin K for biosynthesis, did not change after vitamin K administration
(1.33 IU mL−1).
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Anticoagulant factors
Repeated measurements indicated that the constant but defective amydolitic
activity of PC at baseline was substantially improved by vitamin K supple-
mentation (Table 3.1). Anticoagulant assays indicated a very ample variation
in PC activity (from 2%to 73% of PNP).
Assuming that amidolytic activity parallels or is lower than antigen levels,
the increase in PC specific activity (ratio from 0.06 to 0.8; Fig. 3.3) appears
the most pronounced among the evaluated serine proteases.
Protein S free antigen levels at baseline (Table 3.1) were similar to those
found in type I PS deficiency. Although levels were doubled at 24 h, they
were only partially restored. This pattern was confirmed in the second course
of vitamin K supplementation (Table 3.1).
At 24 h the PS anticoagulant function, evaluated in a PTbased assay,
resulted in 58% of PNP, which roughly normalizes the activity/antigen ratio,
as observed for vitamin Kdependent serine proteases.
The protein C pathway was further investigated through activation of
endogenous protein C by the venom Protac in the APTT-based assay ProC
global [27] (Table 3.1). The normalized ratio at baseline (NR = 0.64) was
comparable with that of a heterozygous FV Leiden plasma (NR = 0.72), and
was substantially increased by vitamin K supplementation (NR = 1.29).
3.4.3 Thrombin and FXa generation assays
The vitamin K-induced modification of thrombin generation parameters was
evaluated under different conditions (Fig. 3.4). At all TF concentrations
the lag-time and time to peak were both prolonged before treatment. In
two plasma samples, obtained severalmonths apart and assayed at 1 pM TF,
the lagtime ranged from 7.7 ± 0.01 to 9.8 ± 0.16 min and the time to peak
from10.3 ± 0.01 to 12.8 ± 0.16 min. By comparison, the PNP lag-time (4.5
± 0.5 and 4.6 ± 0.16 min) and time to peak (8.2 ± 1.17 and 8.6 ± 0.16 min)
were constant. In the absence of TF thrombin generation was undetectable
at 40 min (not shown).
At 24 h after vitamin K supplementation, the lag-time was similar to
normal (Fig. 3.4).Whenmeasured at 1 pM TF (Fig. 3.4) the time to peak
was reproducibly shorter (5.7 ± 0.33 and 6.6 ± 0.16 min) than in PNP.
Before treatment ETP values were clearly reduced at all TF concentra-
tions (Fig. 3.4), ranging from 26% (1 pM TF) to 48% of PNP (10 pM TF).
After treatment, the ETP was close to normal, ranging from 70% (1 pM TF)
to 78% (10 pM TF) of PNP. Normal time parameters (lag-time 4.7 ± 0.01
min, time to peak 7.0 ± 0.01 min) and sustained ETP (61% of PNP) were
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Figure 3.4: Thrombin generation triggered with the indicated TF concentrations in
patient plasma, before (•) and 24 h after (◦) vitamin K administration, and in PNP ().
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still present in the patient’s plasma at 72 h.
In order to enhance the contribution of the APC pathway, thrombin gen-
eration was also evaluated in the presence of the venom Protac (not shown).
This protein C activator substantially inhibited thrombin generation in PNP
(61% reduction in ETP), but was poorly effective in the patient’s plasma,
both before (21% reduction) and after (25% reduction) vitamin K admin-
istration. The ETP measured in plasma from a protein S deficient subject
(PS:C and PS:Ag, 40%) was poorly modified (11% decrease) after the addi-
tion of Protac.
FXa generation was measured with a specific FXa fluorogenic substrate.
The FXa generation after extrinsic activation (Table 3.1) substantially in-
creased following vitamin K administration (from 31% to 77% of PNP), and
was maintained at 72 h (64%of PNP). The time to maximal FXa generation
was consistently shortened at 24 h (from 3.3 to 1.0 min) and similar to that
of PNP (1.1 min). The FXa generation levels at baseline were comparable
with FX antigen levels, and higher than FX activity in the coagulation assay,
further confirming the presence of dysfunctional FX molecules (Fig. 3.3).
3.5 Discussion
The genotyping and characterization of the coagulation phenotype in the
VKCFD2 patient provided us with information that significantly extends
the knowledge of this rare condition, and has general implications for vitamin
K-dependent regulation of plasma factor levels.
It is intriguing that among the several CpG sites (n = 30), potential hot
spots for missense changes in VKORC1, only that contained in codon 98 and
responsible for very low VKORC1 activity has been found to be mutated in
VKCFD2 patients from different countries [5]. Differently, several VKORC1
mutations have been associated with warfarin resistance [5,28,29], a major
clinical phenotype in the anticoagulant therapy. However, themutational
pattern of VKCFD2 is based on very few cases, which prevents an informative
comparison.
The homozygous VKORC1 Arg98Trp change has been found associated
with heterogeneous clinical pictures, ranging fromfatal intracerebral hemor-
rhage after birth [6] to moderate/severe bleeding in adult life in the proposita.
Noticeably, this Italian patient is also homozygous for FVII polymorphisms
predicting further reduction in FVII levels, which could exacerbate bleeding
tendency. From these observations we infer that VKCFD2, caused by a single
VKORC1 mutation, interacts with other genetic/environmental factors with
a major role in the clinical phenotype. The variations of coagulation param-
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eters observed in the proposita before vitamin K supplementations further
support the role of environmental components.
The homozygous condition for the VKORC1 Arg98Trp substitution pro-
vided us with a valuablemodel to investigate in vivo the effect of the limited
availability of vitamin K hydroquinone on coagulation factor levels, and to
compare biosynthetic efficiency of hepatocytes subjected to genetically in-
duced depletion of vitamin K hydroquinone with those poisoned by coumarin
derivatives. FIX, as strongly indicated by its normal antigen levels, showed
the lowest sensitivity to the defective vitamin K cycle, either induced by the
genetic deficiency of VKORC1 or warfarin therapy [8,11].
Interestingly, we found that the functional levels of procoagulant factors
before vitamin K supplementation, which integrate several biosynthetic and
secretion steps in vivo, inversely correlated with the affinity of the vitamin
Kdependent carboxylase for coagulation factor propeptides. Our observation
supports the hypothesis that binding affinities, found in vitro to vary over a
considerable range [25] and to influence the extent of γ-carboxylation [30],
contribute to predict activity level differences in vivo, particularly for FVII,
FX and prothrombin levels and to a lesser extent for FIX.
The similarly reduced protein levels of FVII, FX and PC in the presence
of a wide range of activity levels, produced a gradient in specific activity
among factors (Fig. 3.3), with PC displaying the lowest value. The major
effect of VKORC1 deficiency on this inhibitor does not appear to be mediated
by a preferential impairment in biosynthesis/secretion [14]. The low affinity
of PC formembranes [31], further decreased by reduced γ-carboxylation of
the Gla domain, should substantially contribute to the extremely reduced
PC functional levels in clotting assays, in the lower range of those observed
in patients on stabilized warfarin treatment [32].
Vitamin K supplementation enabled us to investigate temporal variations
in levels of the vitamin K-dependent factors, their effects on overall function
tests and clinical coagulation phenotype. An intravenous single dose of vita-
min K resulted in a fast, efficient and sustained normalization of coagulation
times, as indicated by the integrated assays we used.
The fast amelioration of clotting times and of coagulation factor activity
levels at 4 h after vitamin K supplementation could reflect, in addition to a
de novo biosynthesis, a short time release of proteins accumulated at the in-
tracellular level because of impaired γ-carboxylation. This complexity limits
our ability to measure in plasma the steady state conditions of the vitamin
K-dependent factors. The restoration of the carboxylase activity by vitamin
K supplementation could be also favoured by DT-diaphorase, a NAD(P)H
dehydrogenase, that might play a role in the generation of the hydroquinone
form of vitamin K in the presence of a high concentration of vitamin K
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quinone [33], as probably occurs after vitamin K intravenous administration.
The evaluation of the thrombin generation offered several quantitative
parameters clearly demonstrating the beneficial effects of vitamin K supple-
mentation, particularly the markedly shortened lag-time and time to peak.
In the presence of normalized or borderline activity levels of all procoagulant
factors and PC, the partial restoration of protein S levels would contribute to
the short time parameters of thrombin generation, and to the low response
to Protac. Comparison of thrombograms obtained with different TF concen-
trations provided clear evidence for the gain of information obtained at 1 pM
TF concentration, potentially mimicking the physiological trigger and able
to highlight the effect of reduced protein S levels [34].
The follow up of the coagulation factor levels after transient vitamin
K-induced increase permits a parallel evaluation of their natural decay in
plasma, of great interest for replacement regimens in inherited deficiencies.
Strikingly, the differential decrease in functional levels of endogenous pro-
coagulant vitamin K-dependent factors from the peak to 72 h supports the
lowest half-life values previously estimated in plasma for infused single fac-
tors.
The functional rescue and the uneventful clinical course after invasive
diagnostic procedures suggest that intravenous vitamin K administrations
should be considered the first-line treatment in this condition. However, in-
travenous and oral long-term administrations should be tested in a formal
study to evaluate the effectiveness of vitamin K administration in prophy-
lactic terms.
Taken together our findings in VKCFD2 validate in vivo the cellular and
molecular investigations focused on regulation of circulating factor level ac-
tivity by vitamin K cycle components, and provide evidence for the interplay
between coagulation factor specific biosynthesis and decay after vitamin K
supplementation.
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Chapter 4
Reduced FVII and FVIII levels and
shortened thrombin-generation times during
a healthy diet in middle-aged women with
mild to moderate CVD risk.
Passaro A, Calzavarini S, Volpato S, Caruso P, Poli A, Fellin R, Bernardi F.
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4.1 Abstract
Background: No experimental study has investigated the effect of whole-
diet therapies on a wide range of hemostatic parameters, and their relation-
ship with metabolic and inflammatory markers. Such information was sought
in middle-aged women with moderate cardiovascular disease (CVD) risk sub-
jected to an integrated healthy diet. Methods: Forty-nine premenopausal
womenwere screened for C-reactive protein levels ≥1 mg L−1 and at least one
additional CVD risk factor. Sixteen women (age: 43-54 years) were selected
and received a 12-week diet (four phases) integrating National Cholesterol
Education Program-Adult Treatment Panel-III recommendations with com-
ponents of a Mediterranean-style diet. Results: We observed a reduction
in body mass index (BMI) (P = 0.001), waist circumference (P = 0.005),
total (P = 0.011) and low-density lipoprotein (LDL) cholesterol levels (P =
0.035). Antigen levels of coagulation factor (F)VII (P = 0.003) and FVIII (P
= 0.005) were clearly reduced by dietary intervention, which also appeared
to decrease circulating tissue factor but not fibrinogen and von Willebrand
factor (VWF) antigen levels. Levels of FVIII and tumor necrosis factor-a,
among the inflammation markers, showed the highest correlation, particu-
larly before the intervention (r = 0.55, P = 0.032). Only this cytokine in-
fluenced FVIII variation over time, thus highlighting new relations between
coagulation and cellular components of inflammation. The functional effect
of diet on coagulation was indicated by markedly prolonged thrombin gen-
eration initiation and propagation times (lag time, P = 0.002; time to peak,
P = 0.005). Conclusions: The changes observed in coagulation initiation
and amplification phases, body composition and lipid profile could translate
into a remarkable decrease in the risk for cardiovascular disease. Our obser-
vations suggest novel relationships between coagulation and inflammatory
components.
4.2 Introduction
As diet affects the hemostatic system [1,2], it is a suitable target for inter-
ventions aimed at reducing the risk for cardiovascular disease (CVD) [3,4].
Increased levels of hemostatic factors, including fibrinogen, factor (F) VIII,
FVII, tissue factor (TF) and von Willebrand factor (VWF) have been related
to increased cardiovascular disease (CVD) risk [5-9], in line with the key role
of coagulation factors in thrombus formation. Furthermore, the causal con-
tribution of coagulation factor levels to CVD is supported, although indi-
rectly, by the clinical benefit of anticoagulant therapy in patients with acute
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coronary syndrome [10,11].
During the past decades, the overall CVD mortality has declined but
only a modest reduction has been observed among women [12], which might
suggest that primary prevention programs are less effective in women than in
men. Although changes in life-style in premenopausal women might represent
an effective prevention strategy aimed at enduring risk factor modifications,
little is known about hemostatic variations induced by diet in this population.
The aim of this work was to provide a detailed evaluation of the impact of
a defined intervention strategy on the hemostatic system in pre-menopausal
middle-aged women with a mild to moderate risk for CVD. In particular,
we investigated the effects of an integrated healthy diet on a wide panel
of hemostatic variables and on an overall coagulation functional test. The
rapid turnover of most coagulation factors would enabled us to efficiently
monitor the response to the intervention. Coagulation variations were also
investigated in relation to specific metabolic and inflammatory parameters
previously associated with thrombotic cardiovascular events [13,14].
4.3 Methods
4.3.1 Study population
A group of middle-aged overweight (BMI ≥25 kg m−2) women was invited to
participate in this study. Forty-nine volunteers were screened for eligibility in
accordance with the following inclusion criteria: C-reactive protein (CRP)≥1
mg L−1 in two different assessments; and one or more of the following CVD
risk factors (waist circumference 88 cm; triglycerides ≥150 mg dL−2; high-
density lipoproteins (HDL)-cholesterol <50 mg dL−2; arterial blood pressure
≥130/85 mmHg; plasma glucose ≥110 mg dL−2). Exclusion criteria were:
average daily ethanol intake >30 g over the past 5 years; clinical diagnosis
of diabetes mellitus according to the American Diabetes Association Cri-
teria [15]; diagnosis of menopause according to the American Association
of Clinical Endocrinologists [16]; history of CVD; current therapy with hor-
monal drugs, anti-thrombotics and/or anticoagulants, angiotensin converting
enzyme (ACE) inhibitors, angiotensin II receptor blockers and vitamin sup-
plementation. Fifteen women had CRP levels <1 mg L−2; eight were using
ACE inhibitors or hormonal replacement therapy, one was menopausal, two
had diabetes, one did not have any of the abovestated CVD risk factors, and
six declined to participate. Sixteen women agreed to participate and com-
pleted an independently validated dietary questionnaire on alcoholic intake
and eating habits.
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4.3.2 Intervention
The protocol of this open-label, non-randomized intervention includes four
phases (84 days). We integrated the National Cholesterol Education Program-
Adult Treatment Panel-III (NCEP-ATPIII) dietary recommendations with
the guidelines of the scientific advisory committee of the American Heart
Association, based on the effects induced by a Mediterraneanstyle diet on
the risk of CVD [17]. During the first 21 days (T0- T21), all subjects re-
ceived an isocaloric diet (carbohydrates 57%, proteins 13% and lipids 30%)
according to Therapeutic Lifestyle Changes - ATPIII [4]. The energy intake
was calculated for every subject based on basal metabolic rate and physi-
cal activity levels. Participants were not allowed to consume any alcoholic
beverage, extra virgin olive oil, fish and green or black tea, rich in omega-3,
polyphenols and antioxidants. 180 mL day−1 of monovarietal dry white wine
(11% alcoholic strength) was added at T21. This alcoholic beverage provided
20 g of alcohol/day intake. Based on the postulated anti-inflammatory ef-
fects, during the third phase (T42T63), the diet was integrated with extra
virgin olive oil, low index carbohydrates, salmon and nuts. In the last phase
(T63T84), participants were treated as in T0T21.
A daily food intake diary monitored compliance with the protocol during
the study, and after each phase a clinician assessed any adverse effects. The
Human Research Ethics Committee of the Azienda Ospedaliera-Universitaria
of Ferrara approved the study protocol.
4.3.3 Anthropometric parameters
Anthropometric measurements were taken according to standardized proce-
dures. Fat mass was also determined by tetrapolar bioelectric impedance
analysis (Dietosystem Ltd., Milan, Italy).
4.3.4 Lipids and inflammation markers
After overnight fasting, blood samples were collected at the beginning of
each study phase. Serum and plasma samples aliquots were stored at -80◦C.
Total serum cholesterol and triglycerides levels were determined using stan-
dard enzymatic techniques (Roche Diagnostics, GmbH, Basel, Switzerland).
To measure HDL-Cholesterol, apo B-containing lipoproteins were precipi-
tated from plasma using phosphotungstic acid and Mg2+. LDL cholesterol
was calculated according to Friedewald’s formula. High-sensitivity CRP
(hsCRP) levels were measured (inter-assay coefficient of variation = 5%) by
particle-enhanced immunonephelometry (Roche Diagnostics, GmbH). Serum
68
interleukin-6 (IL-6) and tumor necrosis factoralpha (TNF-α) were quantified
using a commercial ELISA (BioSource International Inc.,Camarillo,CA,USA).
Intra- and inter-assay variation coefficients for IL-6 and TNF-α ranged from
1.8%to 5.4% and from 0.9% to 9.9%, respectively.
4.3.5 Plasma coagulation factors
Antigen levels of TF, FVII and FVIII were determined using a commercial
ELISA (TF American Diagnostica, Greenwich, CT, USA; FVII and FVIII
Affinity Biologicals Inc., Ancaster, Canada). The intra-assay coefficients of
variation for TF, FVII and FVIII assays were 12.8%, 7% and 8.7%, respec-
tively, while the inter-assay coefficients were 14.7%, 7.3% and 7.4%, respec-
tively. To evaluate the VWF antigen levels, we used the ELISA protocol
which is previously described [18]. The intraassay and inter-assay coeffi-
cients of variation for VWF ELISA assay were 6.5% and 15%, respectively.
Antigen levels of FVII, FVIII and VWF were expressed as a percentage of
the healthy plasma in-house pool. Fibrinogen levels were measured using a
prothrombin time-derived method with a turbidimeter kit (Diagen, Thame,
UK).
4.3.6 Thrombin generation measurements
Calibrated automated thrombin activity measurement was performed as de-
scribed elsewhere [19]. Before testing, platelet poor plasma (PPP) samples
were centrifuged at 23 000 x g at 4◦C for 1 h. Coagulation was triggered
in recalcified PPP by addition of 1 pM recombinant human TF and 4 µM
phospholipids (20% phosphatidyl serine and 80% phosphatidyl choline) at
37◦C. All experiments were carried out in duplicate. The assay variability
was lower than 3%. The slope of thrombin generation curves was calculated
using the following formula: {Peak (nM)/[ttpeak (min)-lag time (min)]}.
4.3.7 DNA isolation and analysis of genetic polymor-
phisms
DNAwas extracted from peripheral blood leukocytes using the salting-out
method. The ABO blood group of patients was determined by genotyping
as previously described [20]. FVII gene polymorphisms were analyzed as
described [21].
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4.3.8 Statistical analysis
Data are presented as mean ± standard deviation for parameters with nor-
mal distribution and as median with interquartile range for parameters with
skewed distribution (thrombin generation, hsCRP, IL-6, TNF-α). To ap-
proximate a normal distribution, these variables were analyzed after log-
transformation. Pair-wise correlations were estimated using Pearson’s corre-
lation coefficient. Differences in mean values across study phases were ana-
lyzed using analysis of variance (ANOVA) for repeated measures and anal-
ysis of covariance (ANCOVA). After multiple comparisons, P-values were
adjusted with Bonferroni’s method. Statistical and graphical data analyses
were performed using Stata 9 (StataCorp. 2005. Stata Statistical Software:
Release 9. College Station, TX: StataCorp LP) and R language (R Founda-
tion, version 2.6.1).
4.4 Results
4.4.1 Variation in body composition, lipid and inflam-
matory parameters
Variation in anthropometric, lipid and inflammatory parameters of the 16
women who completed the study protocol are summarized in Table 4.1.
The subjects showed a clear and progressive reduction in BMI (P = 0.001)
throughout the study period. The BMI decline was paralleled by a reduction
in waist circumference (P = 0.005) and, although as a trend, in fat mass (P =
0.096). Total and LDL cholesterol levels were significantly reduced over time
with the most important changes observed after the first study phase (T21
vs. T0; P < 0.05). The degree of change in anthropometric and lipid param-
eters was in good agreement with previous reports [22]. HDL-cholesterol and
triglyceride levels did not show appreciable variation over time, even after
moderate alcohol intake, reported to affect their levels.
At baseline, median CRP was 2.2; nine women had values higher than 2
mg L−1 and five higher than 3 mg L−1. The inflammatory profile did not
significantly change throughout the study although all inflammatory markers,
and particularly IL-6, tended to decrease over time.
4.4.2 Variation in coagulation factors levels
To evaluate the effects on hemostatic components, we determined the antigen
levels of clotting factors mainly synthesized in the liver (FVII, FVIII and
fibrinogen) or in other tissues (VWF and TF) (Fig. 4.1).
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FVII levels showed an appreciable variation (P = 0.003) and the lowest
value was observed at T63 (15.2% lower than T0; P < 0.05), in the presence
of both alcohol and anti-inflammatory components. However, the decrease
was already present at T42 after alcohol introduction (9.5% lower comparing
T42 vs. T0; P < 0.01). The variation pattern did not differ upon exclusion of
subjects heterozygous for the -402 A and -323 10 bp insertion FVII alleles,
known to be associated with increased and decreased FVII levels, respectively
[21,24].
A positive correlation (r = 0.32, P = 0.004) was observed between FVII
and triglyceride values, a well-known determinant of circulating FVII levels
[23]. However, the FVII level variation was influenced neither by parallel
variations in plasma triglyceride nor by fat mass modification, as indicated
by multiple linear regression analysis (ANCOVA adjusted for triglycerides
and fat mass).
During dietary treatment, FVIII antigen levels significantly decreased (P
= 0.005). The reduction was borderline significant at T21, when all subjects
had the same isoenergetic non anti-inflammatory diet, was maximal at T63
(15.1% compared with T0, P < 0.05) and persisted even in the last phase
when alcohol and anti-inflammatory food intake was interrupted.
We found that overall FVIII values were positively correlated with CRP
(r = 0.24, P = 0.034), an important cytokine of the acute phase response,
and TNF-α (r = 0.24, P = 0.043), a pro-inflammatory cytokine associated
with obesity [25]. The positive relation between FVIII and TNF-α levels
was also detected before the intervention (r = 0.55, P = 0.033). FVIII level
variation was not significant after adjustment for TNF-α values (ANCOVA).
Differential adjustment for other inflammation markers, CRP and IL-6, did
not produce a similar effect on FVIII pattern. Over time, the FVIII variations
were not influenced by body fat modifications. Adjustment for blood groups
[26] did not affect FVIII level variation.
Circulating fibrinogen levels, which are an independent CV risk factor
[27], did not show appreciable variations between the different study phases
and were similar to those measured in healthy Italian women [28]. Among
the different inflammatory markers measured, only CRP showed a strong
positive relation (r = 0.54, P < 0.001) with fibrinogen levels at each diet
phase.
Although the statistical analysis of TF levels in plasma is complicated
by the pronounced inter-individual and intraindividual changes, TF levels
appeared to decrease in a stepwise manner during the alcohol and anti-
inflammatory food intake. During treatment, white blood cell counts and
pro-inflammatory protein (IL-6, CRP, TNF-α) distributions could not ex-
plain the TF level variations.
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VWF antigen, a potential marker of endothelial dysfunction or activation,
did not show significant variations over time. A positive relation between
FVIII and VWF levels was clearly detectable, with the highest values at
the beginning of the study (r = 0.58, P = 0.018) and in the presence of
both alcohol and anti-inflammatory components (r = 0.68, P = 0.004). The
variation of the ratio between FVIII and VWF levels showed a pattern similar
to that of FVIII levels (data not shown).
4.4.3 Functional variations of the hemostatic system
We measured thrombin generation in plasma samples using a low concentra-
tion of TF supplied with a non-limiting concentration of phospholipids, as
a sensitive way to monitor the interplay of procoagulant and anticoagulant
components.
The lag time and time to peak (ttPeak) were significantly modified dur-
ing diet treatment (Fig. 4.2). We observedmarkedly prolonged times, and
particularly the median lag time increased from 6.3 (T0) to 8.5 min (T42).
Addition of anti-inflammatory components (T63) did not prolong these times
further, which overlapped at the beginning and end of the study. The en-
dogenous thrombin potential (ETP) and peak parameters did not show ap-
preciable variation during the study and were clearly correlated with FVIII
antigen levels (ETP vs. FVIII r = 0.48, P < 0.001; Peak vs. FVIII r = 0.49,
P < 0.001), as previously observed [29]. The reference plasma showed ETP
and peak values (1285.2 ± 197.4 nmol min−11 and 159.1 ± 42.4 nmol, respec-
tively) similar to those observed in the study population. The modification
of body composition did not influence any thrombin generation parameters
considered.
To further evaluate the relationship between the thrombin generation
rate and the dietary treatments, the slope of thrombin generation curves was
calculated. As indicated by multivariate regression analysis, this parameter
was determined by FVII (β = 0.39, P = 0.01) and FVIII (β = 0.35, P < 0.01)
levels but did not show appreciable variation over time (data not shown).
4.5 Discussion
Although several studies have been conducted on the effects of whole-diet
therapies on CV risk factors [30,31], no experimental study has investigated
the effect on a wide panel of haemostatic parameters, and their relationship
with metabolic and inflammatory markers. The present study reports origi-
nal observations about the beneficial effects of an integrated healthy diet in
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Table 4.1: Variation in body composition, lipid and inflammatory parameters during
dietary phases. Data expressed as mean ± SD. P-values refer to analyses of variance for
repeated measures. Triglycerides, hsCRP, IL-6 and TNF-α are expressed as median and
interquartile range (25th and 75th quartile). *P-values refer to analyses of variance for
repeated measures after log-transformation of the dependent variable.
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Figure 4.1: Over-study variation of hemostatic factor levels. The black line inside
the boxes represents the median value and distribution outliers are indicated with blank
circles (◦). The asterisks indicate significant variation (P < 0.01) with respect to T0 after
Bonferroni’s adjustment for multiple comparisons.
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Figure 4.2: Over-study variation of thrombin generation parameters. The black line
inside the boxes represents the median value and distribution outliers are indicated with
blank circles (◦). The asterisks indicate significant variation (P < 0.01) with respect to
T0 after Bonferroni’s adjustment for multiple comparisons.
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a selected middle-aged female population, characterized by high CRP levels
and at least one additional risk factor for CVD.
Biologically and clinically relevant modifications of body composition,
lipids, coagulation factor levels and thrombin generation parameters were
observed. The reduction in anthropometric and lipid parameters, and par-
ticularly BMI, waist circumference, total and LDL cholesterol levels, would
translate into a remarkable decrease in the risk of CVD.
The antigenic determination of the hemostatic factors, increased levels of
which are recognized or candidate risk factors for CVD, favored the quanti-
tative evaluation of dietinduced biosynthetic changes, and avoided potential
drawbacks of clotting assays.
FVII and FVIII levels were remarkably reduced, whereas fibrinogen con-
centration did not show appreciable changes during the course of the study.
These observations indicate differential effects of diet on those blood co-
agulation factors that are predominantly produced by the liver, a key organ
involved in themetabolic changes observed. Further differences were observed
between the stepwise decrease of FVII and FVIII levels, for which FVIII was
not counteracted by removing alcohol and anti-inflammatory components,
and persisted at the end of the study. VWF levels were strongly correlated
with those of FVIII, but poorly modified by dietary treatments. This obser-
vation, and the similar pattern observed for FVIII levels and FVIII/VWF
ratio, further support a role of diet on modification of FVIII expression.
Diet-responsive anthropometric and metabolic parameters were found to
be associated with coagulation factor levels but did not appreciably influence
any hemostatic factor variations. This pointed towards as yet undiscovered
components in the regulation of coagulation factor expression that were in-
fluenced by intervention.
We observed a clear association between coagulation factor levels and
the inflammatory profile. Levels of TNF-α, a cytokine over-produced by
adipocytes and macrophages of adipose tissue in the obese state [32], were
correlated with those of FVIII and affected their variation over time. This
suggests a previously unknown relationship. As a comparison, CRP, which
is produced by hepatocytes, was strongly related both to fibrinogen [17] and
FVIII but did not affect the FVIII variation over time. These observations
suggest the presence of inflammation- driven crosstalk between hepatic and
extra-hepatic sites for specific regulation of coagulation factor genes.
The functional effects of the dietary treatments were clearly demonstrated
by a comprehensive functional evaluation of the coagulation pathway in
plasma. This meant that the influence of dietary changes upon hemostatic
components could be examined and correlated with the degree of blood hy-
percoagulability. We observed significantly prolonged initiation and propaga-
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tion phases of thrombin generation, which exploit the enzymatic and cofactor
activity of FVII and FVIII, respectively. In spite of the reduction of FVII
and FVIII levels over time and of the estimated influence of these factors on
thrombin generation rate, we did not observe significant relations between
the variations in thrombin generation times and of FVII and FVIII levels.
However, the large number of components, potentially modified by the in-
tervention, that might influence the thrombin generation assay, could mask
these relations.
Some limitations have to be taken into account when interpreting our
findings. The sample size, limited by restrictive inclusion criteria and par-
ticularly by alcohol assumption and the need for persistently increased CRP
levels, precludes detection of small effects of the intervention (i.e. IL-6 and
TF levels). On the other hand, the changes observed even in a small sam-
ple are likely to be biologically and clinically significant. Finally, the study
design, without a formal control group, might be prone to outcome modifica-
tions as a result of secular changes even in the absence of a true intervention
effect. However, the finding of specific and biologically plausible relationships
does not suggest the presence of this type of bias.
In conclusion, the integrated healthy diet produced a differential effect
on coagulation factors, and composite effect on metabolic and coagulation
parameters. The observed variations suggest novel relationships between
coagulation and inflammatory components. The intervention, which is a
feasible approach, sensibly reduced risk factors for CVD in middle-aged pre-
menopausal women, an ideal target for nonpharmacologic primary preven-
tion.
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Chapter 5
Stimulation of P2 (P2X7) receptors in human
dendritic cells induces the release of tissue
factor-bearing microparticles
Baroni M, Pizzirani C, Pinotti M, Ferrari D, Adinolfi E, Calzavarini S,
Caruso P, Bernardi F, Di Virgilio F
Based on: FASEB JOURNAL, 2007, Jun; 21(8): 1926-33.
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5.1 Abstract
Receptors for extracellular nucleotides are the focus of increasing attention
for their ability to cause release of plasma membrane vesicles (microparticles,
MPs). Here, we show that monocyte-derived human dendritic cells (DCs)
stimulated with a P2X7 receptor (P2X7R) agonist undergo a large release
of MPs endowed with procoagulant activity. Functional and Western blot
studies revealed that MPs contain the membrane-bound form of tissue factor
(TF), a glycoprotein acting as essential cofactor of activated factor VII and
triggering blood coagulation. Quiescent DCs express the membrane-bound
(full length), as well as truncated alternatively spliced TF forms. DC reactiv-
ity to anti-TF Abs disappeared almost completely on stimulation with ATP
or benzoyl ATP (BzATP), as shown by immunoblot and confocal microscopy
analysis. Concurrently, TF reactivity and activity appeared in the vesicular
fraction, indicating that MPs are important carriers for the dissemination
of full-length TF form. Activity of MP-bound TF, comparable to that of
relipidated recombinant TF, was dose dependently inhibited by the addition
of a specific anti-human TF antibody. We infer that a large fraction of this
protein, and its procoagulant potential, are “deliverable”after physiological
or pathological stimuli. These findings might have implications for triggering
and propagating coagulation in healthy and atherosclerotic vessels.
5.2 Introduction
Dendritic cells (DCs) were originally identified as antigen-presenting cells
critical for antigen capture and processing and for the activation of naive
T lymphocytes (1-3). DCs are the focus of increasing attention for their
immunomodulatory activity, for their role in resistance to infections and
tumors, and in the induction of tolerance toward normal cell constituents
(4). DCs express several P2 receptor (P2R) subtypes, a feature that makes
them eminently responsive to extracellular nucleotides, as shown by ATP
or UTP-dependent modulation of cytokine production (5-7), upregulation of
chemokine receptors (8), and stimulation of chemotaxis (9). Interestingly,
sensitivity to extracellular nucleotides changes during DC maturation and in
different DCs subpopulations (9, 10).
Nucleotides are present in millimolar concentrations in the cytoplasm
and in the nanomolar range in the extracellular milieu under quiescent con-
ditions. Very active and ubiquitous nucleotide-metabolizing enzymes (ecto-
nucleotidases) have a key role in keeping the extracellular nucleotide concen-
tration low (11, 12). Nucleotides may be released by virtually any cell via
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lytic and nonlytic pathways and P2R present on the DC surface may act as
sensors to monitor their extracellular levels. Although very few studies have
investigated the actual ATP concentration at inflammatory sites, in vivo ob-
servations provide clear evidence for sustained ATP release at foci of tissue
injury and inflammation (13). This may be also relevant for atherosclerosis,
as a very recent report shows that ATP secretion by macrophages modulate
macrophage adhesion to the endothelium, and thus macrophage recruitment
to the atheroma (14).
On the basis of pharmacological, functional, and cloning data, two P2R
subfamilies have been so far described: P2YR and P2XR (15, 16). P2YR
are seven membrane-spanning, G-protein-coupled receptors. Their activation
triggers generation of inositol 1,4,5- trisphosphate and release of Ca2+ from
intracellular stores. P2YR are ubiquitous, being expressed by monocytes,
macrophages, dendritic cells, neurons, smooth and striated muscle cells, as
well as epithelial and endothelial cells (17, 18). P2XR are plasma membrane
channels selective for monovalent and divalent cations that are directly ac-
tivated by extracellular ATP. These channels were originally identified in
mammalian sensory neurons, and subsequently found also in smooth muscle
cells, fibroblasts, and immune cells (17, 19).
DCs express high levels of a peculiar purinergic receptor subtype, previ-
ously known as P2Z (20) and later named P2X7R (21). The P2X7R differs
from the other P2XR for its extended carboxy-terminal domain that endows
this receptor with the ability to form large plasma membrane pores permeable
to small hydrophilic molecules. An interesting property of the P2X7R pore is
its reversibility: removal of ATP triggers resealing of the plasma membrane.
Stimulation of P2X7R by BzATP induces emission of IL-1β containing mi-
crovesicles from the human monocyte cell line THP-1 (22) and from mouse
microglial cells (23).
Circulating microvesicles also referred to as microparticles (MPs) are re-
leased into the bloodstream by a variety of cells. Because of the exposure
of negatively charged phospholipids, in particular, phosphatidylserine, MPs
might provide surfaces that support coagulation. The finding that circu-
lating leukocyte-derived MPs contain tissue factor (TF) further suggests an
important procoagulant function of MPs (24-26).
TF is a transmembrane glycoprotein that acts as the cellular receptor
and essential cofactor for activated factor VII (FVIIa). At the site of vascu-
lar injury, the TF/FVIIa complex triggers coagulation by activating factor
IX and X, ultimately resulting in thrombin formation (27). Moreover, the
FVIIa-TF complex may also play a role in the migration and proliferation
of vascular smooth muscle cells (28), in vascular remodeling and in plaque
neovascularization (29) and thereby in promoting plaque destabilization.
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TF is constitutively expressed in skin, organ surfaces, vascular adventitia,
and epithelialmesenchymal surfaces, where it acts as a sort of hemostatic
envelope (30, 31). In whole blood (blood-borne TF), TF is present in two
forms: a high MW MP-bound, and a low MWsoluble form (asTF) produced
by alternative splicing.
Altered expression of TF has implications in several diseases, particularly
atherothrombosis, where it is crucial in thrombus formation after plaque rup-
ture. TF is thought to be one of the main determinants of the thrombogenic-
ity of the atherosclerotic plaque, and it has been shown that the enhanced
activity of extracellular TF in the lipid core is directly related to the presence
of TF-bearing-MPs (32). Moreover, elevated levels of TF-bearing MPs were
found to be associated with cardiovascular disease (33, 34). Although many
observations indicate the involvement of TF-bearing MPs in atherothrombo-
sis, the cellular and molecular mechanisms responsible for their release are
poorly known.
In the present paper, we investigated the release of TF associated to MPs
in monocyte-derived DCs stimulated with the P2X7R agonist benzoyl ATP
(BzATP).
5.3 Material and Methods
5.3.1 Reagents
ATP was purchased from Roche (Roche Diagnostics SpA, Monza, Italy);
BzATP, benzamidine and phenylmethanesulfonyl fluoride (PMSF) were pur-
chased from Sigma (Sigma- Aldrich, Milan, Italy); EDTA was from Baker (J.
T. Baker, Phillipsburg, NJ, USA); Percoll and Ficoll-Paque were obtained
from Pharmacia (Pharmacia Biotech AB, Uppsala, Sweden).
5.3.2 DC purification
DCs were obtained from peripheral blood of healthy donors, as described
previously (35). Briefly, monocytes were separated by a two-step Ficoll
and Percoll gradient, and then cultured in 2 mM l-glutamine and 25 mM
HEPES-containing RPMI 1640 medium (EuroClone, Milan, Italy) comple-
mented with 10% heat-inactivated FBS (Invitrogen, San Giuliano Milanese,
Italy), 1 mM sodium pyruvate, 1% nonessential amino acids, 200 U/ml peni-
cillin, 20 µg/ml streptomycin (EuroClone), and 0.05 mM 2-mercaptoethanol
(Invitrogen) at 37◦C with 5% CO2, in the presence of 200 U/ml IL-4 and 100
ng/ml GM-CSF (Peprotech, Rocky Hill, NJ, USA).
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5.3.3 MP purification
To increase MP recovery, DCs were stimulated in a solution containing 300
mM sucrose, 1 mM K2HPO4, 1 mM MgSO4, 5.5 mM glucose, and 20 mM
HEPES, 1 mM CaCl2, pH 7.4 with KOH (sucrose solution). After stimu-
lation of the cells with 200 µM BzATP or 3 mM ATP, supernatants were
collected and 1 mM EDTA was added. The protease inhibitors benzamidine
and PMSF were also added. Floating cells and cell debris were eliminated by
centrifuging supernatants for 5 min at 160 g. MPs were purified by centrifu-
gation of cell supernatants at 100,000 g for 90 min, at 4◦C. Vesicle pellets
were then resuspended in the same solution. In samples used for tissue factor
activity measurements, proteases inhibitors were omitted.
5.3.4 Microscopy analysis
DCs were detached from Petri dishes by using 2 mM EDTAcontaining cold
PBS, and then plated (2x105) onto 24-mm glass coverslips (Merck Eurolabs,
Lutterworth, UK). Experiments were performed in the sucrose solution de-
scribed above. Morphological changes and MP shedding were analyzed by
mounting coverslips in a thermostatted Leyden chamber (model TC-202A;
Medical Systems Corp., NY, USA), placed onto the stage of an inverted
Nikon Eclipse TE300 microscope (Nikon Corp., Tokyo, Japan). The images
were captured with a back-illuminated CCD camera (Princeton Instruments,
Trenton, NJ, USA) using the Metamorph software (Universal Imaging Cor-
poration, West Chester, PA). DCs for electron microscope analysis were de-
tached from flasks with 2 mM EDTA-containing cold PBS, and cell pellets
were fixed with 2.5% glutharaldeide. Samples for electron microscopy were
processed by the Centro di Microscopia Elettronica of the University of Fer-
rara (Ferrara, Italy).
5.3.5 Determination of TF cofactor activity
The MPs suspension (10µl) was incubated with 2 nM FVIIa (Novo Nordisk,
Bagsvrd, Denmark) at 37◦C for 10 min in the presence of 5 mM CaCl2
(final volume, 30 µl). 10 nM zymogen factor X (FX) (HTI, Essex Junction,
VT, USA) and 200 µM of a specific fluorogenic substrate for activated FX
(Spectrozyme FXa, American Diagnostic, Stamford, CT, USA) were then
added in a final volume of 100 µl. Fluorescence (excitation 360 nm, emission
465 nm) was immediately measured over time through a SpectraFluor Plus
microplate reader (Tecan, Austria). The assay was standardized by using
serial dilutions (1/7.5-1/480) of Innovin (Dade Bearing, Marburg, Germany)
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in 20 mM HEPES, 150 mM NaCl, 0.1% PEG 8000, 5 mM CaCl2, 100 µM
phospholipid vesicles (PLves 20:80 phosphatidylserine/phosphatidylcoline),
pH 7.4. Inhibition of TF activity by a sheep polyclonal anti-human TF
antibody (HTI) was assessed in a FXa generation assay. To this purpose,
the MPs suspension was preincubated for 20 min at room temperature with
increasing concentrations of the antibody (0-6 nM). The residual cofactor
activity was expressed as a percentage of activity in the absence of antibody.
5.3.6 Western blot analysis
DCs and MPs were lysed by three freeze-thawing cycles, mixed with a solu-
tion containing 60 mM Tris, 2% SDS, 2.5% β-mercaptoethanol, 10% glycerol,
and bromphenol blue and boiled for 5 min. Samples were run on a SDS-PAGE
(4-12%, Bio-Rad, Hercules, CA) and then transferred onto a nitrocellulose
filter (Protran, Schleicher & Schuell, Dassel, Germany). The filter was incu-
bated with a rabbit polyclonal anti-human TF antibody (1 mg/ml, Ameri-
can Diagnostics, Stamford, CT). Secondary antibody was a HRP-conjugated
polyclonal goat anti-rabbit IgG (1 mg/ml, Dako Cytomation, Denmark).
Chemiluminescence was detected with the Supersignal West Femto maxi-
mum sensitivity substrate (Pierce Biotechnology, Rockford, IL, USA).
5.3.7 Immunocytochemistry and confocal analysis
DCs, previously plated onto 13-mm glass coverslips, were incubated for 10
min at 37◦C in a sucrose solution in the presence or absence of 200 µM
BzATP. Cells were then rinsed twice with PBS. All of the subsequent pro-
cedures were carried out at 4◦C, under gentle shaking. Cells were blocked
in 5% goat serum containing PBS for 2 min and then incubated for 1 h
with 40 µg/ml of rabbit anti-human TF IgG, (American Diagnostics). After
3 washes with PBS (10 min each), samples were incubated with 25 µg/ml
goat TRITC-conjugated antirabbit IgG (Sigma-Aldrich) for 1 h in the dark,
washed 3 times with PBS for 20 min, and fixed for 1 h in 2% paraformaldeyde.
Coverslips were then washed 3 times in PBS and mounted onto glass slides in
the presence of Pro Long Antifade solution (Molecular Probes, Leiden, The
Netherlands). Confocal images were acquired with a Zeiss LSM 510 confocal
microscope equipped with a plan-Apochromat 63x oil immersion objective
(Carl Zeiss, Arese, Italy). The 543-nm excitation wavelength was provided
by a HeNe laser source. All images were obtained at a 12% laser potency
and with a pinhole diameter of 135 µm. Amplifier and detector optimiz-
ing parameters were maintained constant for all of the experiments. When
required, a single 3D projection of confocal images on the z axis was ob-
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tained with the LSM examiner software (Carl Zeiss). Fluorescence emission
was quantitated starting from 3D projections with the cell imaging software
MetaMorph (Universal Imaging), as described previously (36). Data were
acquired from 10 to 15 cells per coverslip. An average of 10 coverslips was
analyzed for each experimental condition. Data are expressed in fluorescence
arbitrary units (FU) and shown as mean plus se. Tests of significance were
performed by Students t test and ANOVA by means of GraphPad Instat 3.06
software (GraphPad Software, Inc., San Diego, CA, USA).
5.3.8 RT-PCR
RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA)
and analyzed by RT-PCR (Access RT-PCR System, Promega, Madison WI,
USA) using primers annealing in exon 4 (forward: 5’-GAACGGACTTT-
AGTCAGAAGG-3’) and 6 (reverse: 5’-TGACCACAAATACCACAGCTCC-
3’) of TF gene. RT-PCR for the house-keeping GAPDH gene (forward: 5’-
CCACCCATGGCAAATTCCATGGCA-3’ and reverse: 5’-TCTAGACGGC-
AGGTCAGGTCCACC-3’) was also performed. Amplified fragments were
separated by electrophoresis on a 3% agarose gel, and visualized with ethid-
ium bromide.
5.4 Results
5.4.1 Stimulation of DCs with BzATP induces MP re-
lease
Human DCs challenged with 200 µM BzATP released a large amount of MPs
(Fig. 5.1). Particle release started within seconds of stimulation, usually at
one pole of the cell, and rapidly spread to the whole cell body. Vesicle shed-
ding was preceded by cell contraction and rounding and was paralleled by
a striking increase in plasma membrane blebbing and emission of philopo-
dia. Electron microscopy analysis revealed that BzATP stimulation induced
dramatic changes in cell morphology and a striking plasma membrane reor-
ganization (Fig. 5.2). Similar results were obtained by stimulation with 3
mM ATP (not shown).
5.4.2 MPs show FVIIa cofactor activity
We then asked whether MPs released by DCs showed procoagulant activity.
MPs obtained from different donors were assessed by using a functional assay
88
for TF, based on its property to behave as a cofactor for FVIIa in FXa
generation. MPs had a TF-like activity that was dependent on the amount
of MPs used in the test (Fig. 5.3).
Figure 5.1: P2X7 receptor stimulation induces cell shrinkage and MP shedding from
human dendritic cells (DCs). Cells were seeded onto glass coverslips and stimulated with
200 µM BzATP at 37◦C, as indicated in Materials and Methods. Images were acquired at
5-s intervals with the Nikon Eclipse T-300 microscopy set up described in Materials and
Methods. Arrowheads indicate shedded MPs. Scale bar=10 µm.
Activity of MPs was compared to that of Innovin, a well-known reagent
for TF-dependent activation of blood coagulation. MP activity ranged be-
tween 0.6 and 0.1 nM TF, with a mean value of 38.9±13.8 pM TF/µg MP
protein, i.e., 1.2 fmol/µg MP protein, as the assay was run in 30 µl. Because
DCs release ∼18±7µg of MPs/106 cells, we calculate an activity of released
TF of ∼700 pM TF/106 cells, i.e., 21.6 fmol/106 cells. To rule out the possi-
bility that the FXa generation activity was due to MPs phospholipid content,
phospholipid preparations devoid of TF were also tested. Under these con-
ditions, no fluorescence increase was observed.
As a further proof of a specific role of MP-associated TF in FXa gener-
ation, assays were performed in the presence of increasing concentration of
a specific antihuman TF antibody. As shown in Fig. 5.4, the antibody was
able to reduce, in a dose-dependent manner, the cofactor activity present in
the MP preparation.
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Figure 5.2: Electron microscopy of BzATP-stimulated DCs. Cells were stimulated as in
Fig. 5.1, detached from flasks, fixed with glutharaldeide, and processed for electron mi-
croscopy, as described in Materials and Methods. Arrowheads indicate plasma membrane
extrusions, blebs, and MPs in the process to be released. Scale bars =1µm.
Figure 5.3: TF cofactor activity in MPs from DCs. FXa generation was evaluated as
relative fluorescence over time and compared to recombinant TF (Innovin) and phospho-
lipid vesicles, as controls.  MPs (13.5 µg), N MPs (6.75 µg), H MPs (4.5 µg), MTF (0.6
nM) from Innovin,  TF (0.1 nM) from Innovin, x Phospholipid vesicles only.
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Figure 5.4: Inhibition of MP TF cofactor activity by an anti-TF antibody. Activity was
expressed as a percentage of FXa generation in the absence of polyclonal anti-human TF
antibody (HTI, VT, USA). Duplicate determinations of one of three similar experiments.
Figure 5.5: Expression of TF mRNA in DCs. Lane 1, BzATP-treated DCs; lane 2,
unstimulated DCs. TF, transmembrane form; sTF, soluble form. M, molecular weight
markers.
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5.4.3 Human DCs express the mRNA both for trans-
membrane and asTF
TF mRNA expression in stimulated and unstimulated DCs was investigated
by RT-PCR analysis. To allow the detection of both full-length (transmem-
brane) and soluble (lacking the exon 5- encoded transmembrane domain)
forms of TF transcripts, primers flanking exon 5 were designed.
The amplified fragments (307 bp and 147 bp, Fig. 5.5) are compatible
with the expression in stimulated or unstimulated human DCs of the full
length and soluble (asTF) forms of TF, respectively.
5.4.4 TF protein is associated to MPs released by DCs
The presence of TF protein in DCs and MPs was evaluated through Western
blot analysis with a specific polyclonal anti-human TF antibody. Immunore-
activity to TF was very high in untreated DCs (Fig. 5.6, lane 1), where two
major bands compatible with the presence of both forms of TF protein were
clearly distinguishable. A faint band with high molecular weight, likely cor-
responding to TF dimers, was also present. Comparison of the intensity of
the bands clearly indicated that the transmembrane form was predominant.
Interestingly, the TF immunoreactivity was almost completely lost on stim-
ulation with BzATP (Fig. 5.6, lane 2), thus suggesting that TF was released
Figure 5.6: Western blot analysis of TF in DCs and MPs. Lane 1, untreated DCs; lane
2, DCs stimulated with 200 µM BzATP for 10 min; lane 3, MPs from BzATP-stimulated
DCs. Arrows indicate the membrane-bound (TF) and the soluble (sTF) forms.
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Figure 5.7: Loss of plasma membrane expression of TF on stimulation with BzATP. DCs
were layered onto glass coverslips and either left untreated (A, C-F), or stimulated with
200 µM BzATP for 10 min (B, G-I). Both quiescent and BzATP-stimulated cells were then
incubated in the presence of an anti-TF antibody and further processed for immunoflu-
orescence analysis as described in Materials and Methods. C) DCs were incubated with
the secondary antibody without prior treatment with the anti-TF antibody. A-C show a
z axis projection of the different confocal sections, while D-I show a single confocal plane
cut through the basal (D, G), equatorial (E, H), or apical (F, I) section of the cells. Images
shown are representative of four separate experiments from which at least 15 fields were
acquired for each experimental condition.
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from the cells. In keeping with this hypothesis, the MPs shed from BzATP-
stimulated DCs showed an intense immunostaining for the full-length form
of TF (Fig. 5.6, lane 3). On the contrary, no immunoreactivity for the asTF
form was detected on the MPs. These show that a large amount of TF is
released from DCs by MP shedding.
5.4.5 Expression of TF on DC plasma membrane is
drastically reduced on BzATP stimulation
Changes in TF expression on cell surface were monitored by confocal mi-
croscopy. To this purpose, DCs were incubated with a specific TF antibody.
Confocal microscopy analysis revealed a punctate, bright fluorescence mainly
localized on the plasma membrane and in the peripheral cytoplasm. Fluores-
cence intensity drastically declined on stimulation with BzATP (Fig. 5.7).
DCs incubated in the absence of primary Ab were fully negative, confirming
that fluorescence was not due to unspecific binding of the secondary anti-
body (Fig. 5.7C). Panels A-C show a projection on the z axis of the different
confocal slices, while panels D-I show single confocal planes (basal, D, G;
equatorial E, H; apical, F, I).
5.5 Discussion
The crucial role of TF in the initiation of coagulation (27) as obligatory
cofactor of FVIIa, in the migration and proliferation of vascular smooth
muscle cells (28), in vascular remodeling, and in plaque neovascularization
(29) makes TF expression levels of extreme importance in the control of
early steps of the coagulation cascade and in the thrombogenicity of the
atherosclerotic plaque. Interestingly, increased levels of circulating TF have
been found to be associated with cardiovascular disease (34, 37). In addition,
the Cys186- Cys209 disulfide bond on the surface of TF might be modified
by protein disulfide isomerase (PDI) that inhibits TF thrombogenicity in
a nitric oxide-dependent fashion, thus further linking oxidative stress and
coagulation (38).
The procoagulant activity of MPs found in human atherosclerotic plaques
(32) and the presence at these sites of DCs, expressing high levels of the
P2X7R, suggested to us that ATP released by damaged or infiltrating in-
flammatory cells might trigger release of TF-bearing MPs via stimulation of
the P2X7R. To address this issue, we investigated 1) the ability of human
DCs to release MPs on stimulation of the P2X7R and 2) the presence of
MP-bound TF.
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We found that DCs express the mRNA encoding the full-length form of
TF and, to a lesser extent, the alternatively spliced TF mRNA, as found
in other cell types of hematopoietic lineage (39). The presence of both TF
forms in DCs was confirmed at the protein level by Western blot analyses.
Stimulation of DCs with a potent P2X7 receptor agonist such as BzATP
induced a massive release of MPs. The membrane-bound form was found to
be mainly associated with the MPs, suggesting that most of asTF is directly
released into extracellular space on DC stimulation. TF on MPs was found to
be functional as shown by a fluorogenic assay that allowed to quantitatively
evaluate TF cofactor activity for FVIIa in the stimulation of the physiological
substrate FX.
In our experimental set-up, the addition of DCsderived MPs produced
generation of activated FX, comparable to that triggered by relipidated re-
combinant TF. Although a much more extensive experimentation is clearly
required, these data strongly suggest that MPs are an important source of
procoagulant activity specifically due to TF and not to their phospholipid
content as phospholipid vesicles lacking TF were fully inactive. In further
support of the specific effect of TF-bearing MPs, the procoagulant activity
was largely inhibited by an anti-TF antibody.
It is reported that MPs shedding can be triggered by exogenous stimu-
lants or occur spontaneously even from quiescent cells (40). A higher rate of
MP release is observed in apoptotic cells. Among exogenous stimuli, extra-
cellular ATP has been identified as one of the most potent triggers for MP
shedding, mainly through activation of the P2X7R, although involvement
of other P2 receptors is also likely (22, 23). The physiological significance
of shed MPs is not entirely clear, and even their biochemical features are
still under investigation. However, it is well known that MPs spontaneously
shed by activated or apoptotic monocytes or endothelial cells have a high TF
content and a high procoagulant activity (40).
Our data show that activation of the P2X7R triggers at the same time
a large MP shedding and a massive TF release. Strikingly, analyses of TF
bands in DCs before and after treatment with BzATP revealed that the vast
majority of TF was lost, mainly through MP shedding. This observation
was strongly corroborated by results from immunostaining of TF and confo-
cal microscopy, which showed a punctate immunoreactivity, mainly localized
to the membrane/submembrane area. A similar distribution was recently de-
scribed in rabbit smooth muscle cells and in HEK293 cells transfected with
TF-GFP (41), although in DCs, membraneassociated TF immunoreactivity
was higher than in muscle cells or TF transfectants. Our observations pro-
vide a clear evidence that activation of the P2X7R can trigger depletion of
TF from DCs via shedding of rapidly diffusible MPs. The intrinsic structural
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components of the MPs, such as phosphatidylserine, favor the assembly of
coagulation macromolecular complexes and are likely to participate in the
procoagulant activity together with TF, which is absolutely required to sus-
tain the catalytic activity of FVIIa.
These results indicate that conditions characterized by large release of
ATP into the extracellular space create a strong procoagulant microenviron-
ment due not only to ADP generation from ATP via CD39L1 (NTPDase2)
(42), but also to ATP-stimulated release of TF-bearing MPs. While it is as
yet unknown whether extracellular nucleotides are able to trigger MP release
from platelets (the main circulating source of readily releasable ADP and
ATP), we show here that they maybe be potentially very important for DCs.
DCs and other mononuclear phagocytes are known to infiltrate the vessel
wall and be a major constituent of the atheroma. Platelet aggregation on
a dysfunctional endothelium, or at a disrupted plaque, may quickly release
large amounts of ATP (this nucleotide is costored with ADP within platelet-
dense granules) and generate a propagating wave of procoagulant activity of
which TF-bearing MP may be a main constituent. It is well known that MPs
are a major determinant of plaque thrombogenicity (32). TF release from
DCs might also be precipitated by factors other than platelet aggregation, as
it is increasingly appreciated that ATP is released at sites of inflammation by
immune cells via nonlytic pathways (43). Extracellular ATP might also have
an important role in atheroma formation or in its evolution by stimulating
cytokine secretion, release of proteases or, as recently shown by Wong and
colleagues (14), by modulating monocyte/macrophage recruitment into the
plaque.
Very recently, the mechanism of release of the proinflammatory cytokines
IL-1β and IL-18 has stirred hot interest (44, 45). Two nonalternative vesicle-
mediated pathways seem to be likely involved: 1) a first one based on atypical
secretory lysosomes (46), and 2) a second one based on the release of MPs
(22). To our knowledge, the possible participation of secretory lysosomes in
TF release has not been investigated but we cannot exclude that this path-
way might also be involved. Our current protocol for DC stimulation and
MP harvest included incubation of DCs in low salt buffer, an experimental
condition that on one hand improves MP recovery, but on the other that
might also enhance TF targeting to MPs and obscure the contribution of se-
cretory lysosomes or other possible export pathways. In any case, whichever
the relative contribution of these two pathways to TF externalization, DC-
derived MPs also contain IL-1β (47), thus it might well be that activated
DCs release membrane-bound boluses of costored proinflammatory and pro-
coagulant factors.
An often asked question is whether ATP is the true physiologically rele-
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vant stimulus for the P2X7R. Scattered evidence suggests that the P2X7R
might also be activated by different stimuli such as antimicrobial peptides
released by polymorphonuclear leukocytes (48). This might suggest that
additional proinflammatory factors that are generated in the atheromatous
plaque or at other sites of vessel wall inflammation may cause release of
TF-bearing MPs by acting at the P2X7R.
In conclusion, our observations identify a novel pathway for TF release
from DCs and provide new insights into the mechanisms underlying the gen-
eration and spreading of procoagulant activity in immunity and inflamma-
tion.
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General discussion
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6.1 General discussion
During the last decades, there has been increasing attention to plasma levels
of specific coagulation factors, or inhibitors, or to functional coagulation
parameters able to predict a risk for thrombotic or haemorrhagic events.
The Thrombin generation assay, aimed at monitoring the generation of the
last effector of the clotting cascade, is certainly a valuable candidate. The
features of the Thrombin generation curve provide information on different
steps of the process, the lag phase on the initiation phase triggered by the
extrinsic pathway and the peak on the propagation phase characterized by a
thrombin burst, which is eventually completely inhibited by plasma protease
inhibitors (termination). The area under the curve, known as the endogenous
thrombin potential (ETP), represents the total amount of active thrombin
formed (Fig. 6.1).
Figure 6.1: Thrombogram and parameters
Several studies have shown that the ETP is a good overall indicator of
prothrombotic [1–6] and haemorrhagic tendency [1, 7–10]. However, only
sporadic attempts have been made to elucidate the effects of single coagu-
lation factors on thrombin generation [11–13], thus leaving the relationship
between levels of coagulation factors/inhibitors and the various parameters
of the thrombin generation curve (lag time, ETP and peak height) still an
open question.
A recent study addressed this issue in a healthy population [14]. In par-
ticular, the thrombin generation parameters were evaluated by varying the
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concentration of the procoagulant trigger, Tissue Factor, and by adding an-
ticoagulant factors such as Thrombomodulin and Activated protein C to
plasma samples. Under each condition, the lag time reflects the initiation
phase of thrombin generation, while the peak height and the ETP (which are
highly correlated) probe the propagation and termination phases of coagu-
lation. Thrombin generation test could be a useful overall assay to identify
the impact on the clotting process by fluctuations of levels of key protein of
coagulation.
A number of molecular mechanisms, acting at different levels of the gene in-
formation flow, could produce variations in the expression of these proteins.
The genetic component, producing a lifelong effect, is certainly the major
determinant of levels in most factors.
Beside the gene mutations responsible for disease states i.e. hemophilia or
thrombosis, there is a number of more subtle gene changes, the so-called
polymorphisms, that are able to tune coagulation protein or activity levels.
Gene changes might influence the expression of clotting proteins by occurring
either in their specific genes or in genes encoding for proteins involved in the
correct biosynthesis of coagulation factors (modifiers).
The evidence that, not infrequently, the same mutation is associated to dif-
ferent clinical phenotypes, support the hypothesis that individual polymor-
phisms confer a marginal to moderate risk factor in pathology that becomes
evident only across many thousands of individuals.
Intragenic components
All these observations are consistent with the common idea that several
pathologies are caused by the interplay among multiple genetic and envi-
ronmental factors which jointly concur to the development of the disease.
This is the case of the Coronary Artery Disease (CAD), a multifactorial dis-
ease in which are involved many biochemical pathways and intermediate phe-
notypes (e.g. hyperlipidemia, diabetes, hypertension), each in turn under the
control of many genes. Evidence that a hypercoagulable state is associated
with increased mortality has been provided [15, 16], and so it is biologically
plausible that the simultaneous presence of several genetic variations with
modest effects on the hemostatic process could be relevant in rising the risk
of the major thrombotic complication, i.e. Myocardial Infarction (MI). We
investigated [Martinelli et al. 2008] the combined effect of several common
prothrombotic polymorphisms (fibrinogen β-chain -455 G/A, Prothrombin
20210 G/A, Factor V Leiden, Factor V R2, Factor VII A1/A2, Factor VII
-402 G/A) on the risk for MI, in a selected population of high risk patients
with angiographically documented, advanced CAD. The prevalence of MI
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increased linearly with an increasing number of unfavorable alleles.
The association between genotypes with variations in the thrombin genera-
tion parameters was subsequently investigated in a subset of these patients,
to reveal potential acquired risk-phenotype due to the stratication of vari-
ables. In thrombin generation measurement, the presence of FV Leiden, the
FII G20210A mutations have been already found to be associated with in-
creased thrombin generation [17, 18]. It was experimentally proved that the
lag time of thrombin generation was influenced by fibrinogen and FVII, in
line with the notion that the coagulation cascade is initiated by binding of
TF to FVIIa; moreover determinants of the amount of thrombin formed were
again fibrinogen and also prothrombin level but with high procoagulant stim-
uli, possibly because only a fraction of the prothrombin present in plasma is
activated at low TF [14].
In our study, the thrombin generation activity was assessed as a function of
the number of procoagulant alleles (fibrinogen β-chain -455 A, Prothrombin
20210 A, Factor V Leiden, Factor V R2, Factor VII A1, Factor VII -402 A).
The selected patients were divided in order to form three groups matched for
age and sex representing increasing risk-factor groups.
Figure 6.2: Comparison between the median thrombin generation activity curves in
groups stratified on the basis of number of procoagulant alleles, with a threshold level at
5 alleles.
We found a clear association between the number of procoagulant alleles
and thrombin generation parameter i.e. Endogenous Thrombin Potential
(ETP) Fig. 6.2. While individual genetic susceptibility variants are of limited
clinical use, the combined information from a number of these variants can
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permit the identification of groups of people at high and low risk of developing
a complex trait such as MI [19, 20].
This approach, applied on a larger scale, could be a predictive model for risk
evaluation, and the thrombin generation assay, measuring the cumulative
effect of pro-thrombotic tendencies, in the frame of an integrated study, may
be suitable for this purpose.
Extragenic components
Significant variations in clotting proteins levels can originate from direct in-
tragenic variation but also by variations in genes encoding proteins involved
in the biosynthesis and processing of clotting factors. A valuable model to
assess the influence of modifiers on the levels of different circulating vitamin-
k-dependent clotting factors is represented by deficiency of components of the
vitamin-k-cycle, essential for the γ-carboxylation. γ-carboxylation is a key
post-translational modification of many coagulation factor, which is essential
for proper folding of their Gla domain and for the interaction with negatively
charged phospholipid surfaces. Previous studies have identified a mutation
in the vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) gene
that is responsible for impaired γ-carboxylation of vitamin-k-dependent clot-
ting factors. We took advantage from the identification of this mutation in a
italian patient to perform an extended analysis of the coagulation phenotype
associated to VKORC1 deficiency [Marchetti et al. 2008].
Antigen protein’s levels at baseline were markedly reduced except for FIX,
whose levels appeared to be poorly influenced by defective Vitamin K cy-
cle. Functional levels of procoagulant proteins before intervention, inversely
correlated with the affinity of the vitamin-K dependent carboxylase for coag-
ulation factor propeptides, according to the hypothesis that weaker affinity
for the carboxylase, results in more efficiently carboxylated product due to
an increase in off-rate and hence altered catalytic turnover [21]. Time course
analysis evidenced that a single dose of vitamin K normalized coagulation
times and plasma factor levels and activity. This partial restored normal
phenotype persist over 24 hours.
The thrombin generation assay was also exploited to evaluate the effects on
the overall coagulation phenotype. In order to highlight different contribution
of vitamin k-dependent clotting factor to thrombin generation, increasing TF
concentrations were used to trigger the reaction Fig. 6.3. Testing the throm-
botic potential under different procoagulant stimuli emphasize the beneficial
effect of vitamin-K supplementation. All thrombin generation assay’s param-
eters were significantly restored, after vitamin k injection, compared with a
normal plasma control.
107
Figure 6.3: Thrombin generation triggered with the indicated TF concentrations in
patient plasma, before (•) and 24 h after (◦) vitamin K administration, and in PNP (-).
In addition, differential TF concentrations led others quantitative con-
siderations. Since observed partial restored PS levels could influence the
initiation phase of thrombin generation [14, 22, 23], shortened time param-
eters of thrombin generation, lag time and time to peak, clearly contribute
to this hypothesis. All these observations provide evidence for the interplay
between coagulation factor specific biosynthesis and decay, after vitamin K
supplementation.
Acquired components
It is well-established that acquired components, also related to human be-
haviour and habits, have a strong influence on the expression of many coag-
ulation factor, and might represent independent risk factor for disease.
Conditions such as obesity [24, 25], oral contraception [26, 27], hormone re-
placement therapy [27], age [28], alcohol intake [29] and potentially smoking
[30], could enhance risk for thrombotic events.
Epidemiological studies have demonstrated that in a given population, diet,
with other several environmental factors, is an important determinant of risk
of vascular disease and mortality [31].
Hence the effect of whole-diet therapies on hemostatic parameters and their
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relationship with metabolic and inflammatory markers, could represent an
interesting approach to address this issue.
Our study [Passaro et al. 2008] was aimed at evaluating the effects of a
Mediterranean style diet on coagulation parameters that represent risk factor
for cardiovascular disease (CVD) [32].
Measurements were conducted in a middle aged population of overweighted
woman with high levels of C-Reactive Protein (CRP), an important cytokine
of acute phase response, and at least another CVD risk factor. Observed
reduction of anthropometric and lipid parameters, as already reported [33],
would translate into a remarkable decrease in the risk of CVD.
After progressive introduction of proved anti-inflammatory dietary elements,
such as wine [34, 35] or fish [36], all inflammatory markers, and particularly
IL-6, tended to decrease over time, even though not significantly.
We found a clear association between coagulation factor levels and the inflam-
matory profile. Levels of Tumor Necrosis Factor-α, a cytokine over-produced
by adipocytes and macrophages of adipose tissue in the obese state [37],
were correlated with those of FVIII and affected their variation over time.
The observed variations suggest novel relationships between coagulation and
inflammatory components. It has been reported that increasing levels of
hemostatic factors, including fibrinogen, FVIII, FVII, TF and vWF are re-
lated to increased CVD risk [38–42], in line with the key role of coagulation
factors in thrombus formation; moreover, plasma from females is more proco-
agulant than in males, as indicated by the tendency towards shorter lag times
and higher ETPs and thrombin peaks [14]. This suggest that the eventual
influence of dietary changes upon hemostatic components could be examined
and correlated with the degree of blood hypercoagulability.
We found that FVII and FVIII levels were remarkably reduced during the
course of the study, and FVIII decrease persisted over the dietary intake.
Also temporal parameters of thrombin generation, lag time and tt peak,
were significantly prolonged Fig. 6.4, perhaps reflecting changes related with
initial stages of coagulation cascade. In spite of this evidences, we did not ob-
served significant relations between variations in thrombin generation times
and FVII and FVIII levels.
Moreover, since the “rate”of thrombin generation is considered the key vari-
able to stable fibrin clot formation [43, 44], we have calculated the slope of
thrombin generation curves, but no significant correlation was observed over
time. However a large number of components potentially modified by the
intervention and not directly quantified, might influence the thrombin gen-
eration assay, masking possible relations.
Changes observed overtime reinforce the relationships between coagulation,
environment and inflammatory components; and suggest monitoring of co-
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Figure 6.4: Over-study variation of thrombin generation parameters. The black line
inside the boxes represents the median value and distribution outliers are indicated with
blank circles (◦). The asterisks indicate significant variation (P < 0.01) with respect to
T0 after Bonferroni’s adjustment for multiple comparisons.
agulation parameters as an informative tool for evaluating short-term effects
of diet therapy.
Cellular components
Mechanisms involved in the intracellular and extracellular trafficking of pro-
teins could represent another important level of control of coagulation factor
levels. This is certainly the case for Tissue factor (TF). In fact, it has been
demonstrated that, beside the transmembrane and the soluble forms, TF
circulates into the blood stream bound to cell-derived microparticles (MPs).
TF-bearing MPs, providing a suitable phospholipid surfaces for the assembly
of coagulation complexes [47, 48], have been receiving increasing attention
in recent years as potential vehicles of biological informations through blood
vessels. The crucial role of TF in the initiation of coagulation [45] as oblig-
atory cofactor of FVIIa, in migration and proliferation of vascular smooth
muscle cells [46], in vascular remodeling, and in plaque neo-vascularization,
makes TF expression levels of extreme importance in the control of early steps
of the coagulation cascade and in the thrombogenicity of the atherosclerotic
plaque.
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In our study [Baroni et al. 2007] we tested the hypothesis that dendritic cells,
an important components of the atherosclerotic plaque, can express and re-
lease TF-bearing MPs upon stimulation.
Our data clearly showed that blood monocyte-derived human dendritic cells
are able to express, endogenous TF mRNA and protein also in a “solu-
ble”variant engendered from an alternative splicing process. It has been
previously demonstrated that DCs upon stimulation with benzoyl ATP, a
potent agonist of the more physiologic ATP, through Its signalling via P2X7
receptors, are able to release MPs [49] Fig. 6.5. In our study we demonstrated
that a fraction of these MPs contains TF.
We found TF to be functional as shown by a fluorogenic assay allowing to
Figure 6.5: P2X7 receptor stimulation induces cell shrinkage and MP shedding from
human dendritic cells (DCs).
quantitatively evaluate TF cofactor activity for FVIIa in the stimulation of
the physiological substrate FX.
Blood DC migrating into the sites of vascular injury or inflammation, are
activated under high thrombin concentrations and secrete proinflammatory
cytokines, which subsequently modulate coagulation or other physical acti-
vation [50]. Under certain stimuli, such as plaque erosion or rupture, the
concomitant presence of platelets, that may quickly release large amounts of
ATP (costored with ADP within platelet-dense granules), and Dendritic cells,
expressing high levels of the P2X7 receptors, may predispose to sustained
thrombin generation leading to the acute thrombotic event. This complex
regulatory network evidences the potential physiological significance of shed
MPs, as confirmed by our observations, even if their biochemical features are
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still under investigation.
6.2 Conclusions
Our studies provide evidence for genetic and environmental determinants of
coagulation factor levels in plasma, and for their integrated effects on gen-
eration of thrombin. The interplay between these components is responsible
for ample individual variations in the coagulation phenotype. These find-
ings have implications on the diagnosis, prophylaxis and therapy of coagula-
tion diseases, and encourage further investigations to better understand the
clinical significance of the molecular heterogeneity of the human hemostatic
proteome.
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Summary
Background
The maintenance of blood fluidity within the vascular system is ensured by
the balance between procoagulant and anticoagulant components. Hemosta-
sis and blood coagulation are processes regulated by a complex network of
interactions, involving plasma/tissue proteins and cells. Numerous epidemi-
ologic studies indicate that deciencies in blood coagulation proteins cause
serious bleeding problems, whereas the deciencies in coagulation inhibitors
and certain mutations in coagulation factors may lead to thrombotic disor-
ders. The coagulation process has been conceptualized as being dependent
primarily on adequate levels of the coagulation proteins. From clinical stud-
ies it is assumed that the normal concentration range of proteins involved
in blood coagulation and regulation of this process may vary in the average
blood sample from 50% to 150% of their mean plasma values. This suggests
that a wide range of factor levels is compatible with normal hemostatic func-
tion; however, even within the normal range, variations can affect the rate
and extent of thrombin generation. As a consequence, the stimulus/response
which follows tissue factor presentation to blood and the subsequent expres-
sion of thrombin activity is highly variable even in the normal population.
In addition, the qualitative performance of these proteins is governed by
many molecular events which are influenced both by genetic background,
and by environmental processes that alter coagulation proteins during cir-
culation and may produce very different phenotypic responses. All these
considerations emphasize the importance in measuring and monitoring vari-
ations of coagulation factor levels, providing potential correlations with non
physiologic conditions. Also, the evidence of how the coagulation proteins
are involved in the acute phase of inflammation and several other human
diseases, confirm that analysis of their level changes and modulation, repre-
sent the way required for appropriate diagnosis and therapeutic intervention.
Aims
A number of molecular mechanisms intragenic, extragenic and environmen-
tal, acting at different levels of the gene information ow, could produce vari-
ations in the expression of coagulation protein or activity levels. To get
inside this complex regulative network we report four different studies aimed
at elucidate aspects of clotting factor modulation. Study of oscillations in
coagulation factor levels, due to inherited or environmental factor, could
establish novel relationships between coagulation and inflammatory compo-
nents, or with determinant of other human pathologies.
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Methods
Methods are included in articles published in 2007/2008; they are focused on
thrombin generation assay, an overall assay measuring the amount of throm-
bin produced in plasma samples in standard condition. This method evi-
dences subjects coagulation-phenotype, allowing the correlation with other
clotting factors levels.
Main Results
The combined effect of ten common prothrombotic polymorphisms as a de-
terminant of MI was tested in a population of 804 subject, half of whom
affected by severe Coronary Artery Disease (CAD). The number of proco-
agulant alleles was significantly associated with the Endogenous Thrombin
Potential (ETP), similarly, subjects with a high number of procoagulant al-
leles had significantly higher ETP values as compared to subjects with fewer
alleles.
Similar approach was used to investigate a rare bleeding disorder, vi-
tamin K-dependent clotting factor deficiency type 2 (VKCFD2), which of-
fered several quantitative parameters providing us information on vitamin
K-dependent regulation of plasma factor levels; a markedly variation in
Thrombin Generation parameters and others clotting factors measurements
improved the identification of a clear coagulation phenotype.
We also probed the effects of an integrated healthy diet on a wide panel
of hemostatic and inflammatory variables. The changes observed in coagula-
tion initiation and amplification phases, body composition and lipid profile
could translate into a remarkable decrease in the risk for cardiovascular dis-
ease, suggesting novel relationship between coagulation and inflammation
components.
Finally we investigate how Tissue Factor-bearing Microparticles was gen-
erated by monocyte-derived Dendritic Cells stimulated with the P2X7R ag-
onist benzoyl ATP (BzATP); our observations identify a novel pathway for
tissue factor release, providing new insights into the mechanisms underlying
the generation and spreading of procoagulant activity. The activity of this
potential circulating trigger of coagulation and inflammation stimuli could
be involved in progression of several pathology and inflammation process.
Conclusions
Our studies provide quantitative evidence for genetic and environmental de-
terminants of coagulation factor levels in plasma, and for their integrated
effects on generation of thrombin. The consequent variation of coagulation
phenotype produces ample temporal and individual variations in coagula-
tion function. These findings have implications on the diagnosis, preven-
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tion/prophylaxis and therapy of coagulation diseases, and encourage further
investigations to better understand the clinical significance of the molecular
heterogeneity of the human hemostatic proteome.
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